IMPROVING MEDICATION SAFETY IN COMMUNITY PHARMACY: ASSESSING RISK AND OPPORTUNITIES FOR CHANGE

==

....

...



. . .

a nonprofit organization



Table of Contents

Table of Contentsi
Introduction1
Illustrating the Application of Key Elements of the Medication Use System™ to Assess Risk
Key Element I: Patient Information5
Key Element II: Drug Information9
Key Element III: Communication of Drug Orders and Other Drug Information 13
Key Element IV: Drug Labeling, Packaging, and Nomenclature
Key Element V: Drug Standardization, Storage, and Distribution
Key Element VI: Medication Device Acquisition, Use, and Monitoring
Key Element VII: Environmental Factors, Workflow, and Staffing Patterns 42
Key Element VIII: Staff Competency and Education
Key Element IX: Patient Education53
Key Element X: Quality Processes and Risk Management
Final Quick Check Question
Using the Assess-ERR™ Tool in Community Pharmacy
Illustrating the Application of the Key Elements through the Medication Flow Process
Utilizing the Assess-ERR™ (Case Study)
Conclusion
Acknowledgements97
References
Glossary
Appendix 1: ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations
Appendix 2: FDA and ISMP Lists of Look-Alike Drug Name Sets with Recommended Tall Man Letters
Appendix 3: Assess-ERR™ (Community Pharmacy Version)
Appendix 4: Strategies to be used with the Assess-ERR™ (Community Pharmacy Version)
Appendix 5: Selected Data from ISMP Medication Safety Self Assessment [™] for Community/Ambulatory Pharmacy



Introduction

The Importance of Systematic Analysis of Errors in Pharmacy Practice

The 2006 Institute of Medicine (IOM) report *Preventing Medication Errors* estimated that, based on studies and referenced research, 51.5 million errors occur per 3 billion prescriptions per year.¹ This amounts to four errors per 250 prescriptions per pharmacy per day. The IOM further estimated that 6.5% of these errors were clinically significant. By extension, this translates to one clinically significant error per 962 prescriptions.

Using these estimates, a typical community pharmacy that fills about 2,000 prescriptions per week may generate up to two clinically significant prescription errors every week.

Surely there is room for improvement. This manual has been designed to assist community pharmacy practitioners and operators to assess their current practices and enhance their procedures for improving safety in their practice settings.

The goal of every community pharmacy should be to continually improve their medication-use system in order to help ensure the safest, highest quality of care possible. To accomplish this, community pharmacies must assess their risks associated with the medication-use process by monitoring actual and potential medication errors and adverse events that occur within their organization. Analysis and investigation of root causes of these events must then occur so that strategies to improve the medication-use process and prevent future events may be identified and implemented. Key to success is the quality of the information collected in the reports, the analysis of the information, and the subsequent actions taken to improve the system and prevent harm to patients.

The ISMP Medication Safety Self Assessment[™] for Community/ Ambulatory Pharmacy was developed in 2001 and made available to community and ambulatory pharmacies for the purpose of encouraging individual pharmacies to self evaluate their processes. Data collected from the more than 5000 pharmacies that completed the self assessment indicates a lack of implementation of patient safety initiatives in current practice. (To view examples of data that was collected from the ISMP Medication Safety Self Assessment[™] for Community/Ambulatory Pharmacy in each of the key elements, see Appendix 5.) Therefore this "Improving Medication Safety in Community Pharmacy: Assessing Risk and Opportunities for Change" manual was developed to educate community pharmacists on the key elements of the medication-use system in order to self analyze errors and prioritize safety changes that should be employed.



Goals

The goals of this manual are to:

- Raise awareness of error-prone processes in the medication delivery system.
- Build awareness of risk-identification opportunities in the community pharmacy setting.
- Maximize the appropriate application of system strategies to reduce organizational risk.

Outcomes

After utilizing this manual, community pharmacy personnel will be able to:

- Initiate a risk assessment process to identify medication safety improvements in the community pharmacy setting.
- Use *ISMP's Key Elements of the Medication Use System™* to help identify and prevent risk in daily practice.
- Examine flow diagrams or flow charts of the medication process to identify variability in current medication-use processes.
- Select effective error reduction strategies that can prevent patient harm.
- Review case scenario(s) of medication error or near miss events and apply knowledge of *ISMP's Key Elements* to identify breakdowns in the system that have contributed to the error.
- Utilize the Assess-ERR[™] for a medication error or near miss that has occurred in your practice

This manual is designed to help community pharmacy personnel identify potential medication safety risks and prevent error. Pharmacists can use the materials and tools in this manual to pinpoint specific areas of weakness in their medication delivery systems and to provide a starting point for successful organizational improvements.



Illustrating the Application of Key Elements of the Medication Use System[™] to Assess Risk

Background

This manual contains modules pertaining to *ISMP's Key Elements of the Medication Use System*TM (table below). These are the factors that most significantly influence the medication-use process and safe medication use. The interrelationships among these key elements form the structure within which medications are used.^{2,3}

ISMP's Key Elements of the Medication Use System [™]				
I	Patient information			
П	Drug information			
111	Communication of drug orders and other drug information			
IV	Drug labeling, packaging, and nomenclature			
V	Drug standardization, storage, and distribution			
VI	Medication device acquisition, use, and monitoring			
VII	Environmental factors, workflow and staffing patterns			
VIII	Staff competency and education			
IX	Patient education			
Х	Quality processes and risk management			

The following individual key element sections contain:

- An example of an actual reported error involving the identified element and recommendations specific to the reported error.
- Printable charts containing contributing factors and strategies of recommended actions pharmacists can take to advance medication safety in that particular key element.
- A "Quick Check" risk assessment question related to that element.

Key Elements provide learning experiences

To identify common failure points that lead to errors, the contributing factors in each key element that follow can be used as learning tools when evaluating the safety of medication use within your pharmacy. The subsequent risk reduction strategy charts are valuable aids to identify risk and prevent future error. These contributing factors and error prevention strategies may also be used to stimulate



discussion regarding day-to-day safe practices in conversations among frontline staff and during supervisor field visits.

Improving patient safety is an ongoing process that demands continual review. The content in the following modules will provide you with proven strategies that can be implemented to practice in a more patient safety-focused environment.



Key Element I: Patient Information

Essential patient information is obtained, readily available in useful form, and considered when dispensing medications.

Background

Information about the patient guides the appropriate selection of medications, doses, and routes of administration. Of significant importance is basic demographic and clinical information (e.g., age, weight, allergies, diagnoses and pregnancy status) as well as patient monitoring information (e.g., laboratory values, vital signs and other parameters) that gauge the effects of medications and the patients' underlying disease processes.

Studies have shown that as many as 18% of serious, preventable adverse drug events (ADEs) stem from practitioners having insufficient information about the patient before prescribing, dispensing and administering medications.⁴ Twenty-nine percent of prescribing errors alone are directly associated with inadequate patient information.⁵ Narcotics and antimicrobials are the two drug categories most frequently involved in errors related to insufficient patient information. Most serious injuries are due to prescribing these drugs for patients allergic to them.

Error with Patient Information causative factors

Patients with very similar names and very similar dates of birth led to a dispensing error. Jane F. Doe, (date of birth 6/17/1955) was given Jane S. Doe's (date of birth 6/13/1955) medication in error at the check out window. Patient took one tablet (glipizide extended release 10mg) and was admitted to the hospital with low blood sugar. Neither patient had an up-to-date profile indicating health condition; neither patient accepted the offer to counsel and there was no notation in the pharmacy computer system indicating or warning of patients with same/similar names.

Recommendations

Correctly dispensed prescription handed to a patient for whom it was not intended is an error that can be avoided by consistent use of a second patient identifier. Pharmacy personnel should ask the person receiving the prescription to state the patient's address or date of birth, and compare their answer to the information on the prescription receipt. Do not tell the patient the address or date of birth and ask them to confirm the information. The ISMP MERP has received numerous reports of patients who have indicated "yes" that the address was correct only to take home someone else's medication. Prescribers and pharmacists should have computerized notes to warn about previously detected patients with similar names. Flags should appear when these patients are selected during patient data entry. Patient education sessions should include discussion of the purpose of the medication, to



help ensure the correct medication is being dispensed to the correct patient. In addition, patient demographics, including health condition codes, should be updated on a regular basis in each patient's profile. Medication indications should match health conditions, unless the medication is knowingly being prescribed off-label.

I. Common Contributing Factors Involving Patient Information

Absent or unclear patient identity

Missing patient address

Age (date of birth), especially if child under 6, not noted or taken into consideration

Weight (pediatric) unavailable or unit-of-measure not indicated (lbs vs. kg) for proper dosing calculations

Allergies unknown or not updated

Allergy information is not integrated into the pharmacy computer system

Pregnancy status not known or considered

Co-morbid conditions (e.g. diabetes, hypertension) not known

Demographic and health information not collected on new patients

Previous drug history not known

Health conditions, diagnosis, allergies in computer system or on hard copy prescription but system not integrated, so drug alerts do not appear

Diagnosis not clear

Unique patient identifiers not used at point of sale

I. Patient Information Risk Reduction Strategies

Prescription Drop-Off Stage

Ask for patient allergy information at every visit and validate against the patient profile; distinguish between No Known Allergies (NKA) and Unknown Allergies

For visually or hearing impaired patients, provide alternate means of communication so available patient information may be obtained

Obtain clinical purpose of each prescription before the medication is dispensed, to assure that the prescribed therapy is appropriate for the patient's condition and to help distinguish medications with similar packaging and look-alike or sound-alike names

Obtain alternate means of communicating with patient; in addition to home phone number collect and store cell and work phone numbers and email addresses as applicable



I. Patient Information Risk Reduction Strategies

Routinely ask for patient diagnosis and co-morbid conditions, including pregnancy, and add this information to computerized patient profile

When transcribing spoken orders, use telephone prescription pads that are designed with prompts for allergy information, weight in kg for children under six years old, and drug indication

Ask for two patient identifiers when receiving telephonic prescription orders

Implement policies and procedures or system enhancements to insure one profile per person exists in system; be cognizant of name suffixes (Jr.), first/last name interchanges and incorrect assignment of first and last name (James John or Ikembe Fintumbo); if applicable utilize legal name or name on insurance card

Be sure date-of-birth is noted on every prescription hard copy and clearly visible on prescription receipt

Obtain/validate patient weight when filling pediatric medications

Annually update patient demographic information

Order Entry Stage

Properly code allergy information in computer system to allow for computer system screening

Design a computer system that prohibits dispensing when no allergy information is in the patient profile

Drug Utilization Review (DUR) Stage

Ensure that the drug ordered matches the clinical indication provided and does not interact with other medications on the patient profile

Ask patient for medication (other prescriptions, over-the-counter [OTCs], herbal and dietary supplements) not filled as prescriptions at this pharmacy, and add them into the computer system to be part of the drug utilization review (DUR) screening

Highlight the date-of-birth, for children under the age of six, in computer system, on receipt and on prescription hard copy to avoid errors in dosing and dosage forms

Identify patients who are eligible for Medication Therapy Management Services (MTMS)

Pick-up Stage

Confirm allergies at pick up

Provide patient with updated medication list annually; confirm list with patient

Know each patient's language of preference, education or reading ability level, and if any visual or hearing impairments exist, in order to counsel at their level of competency

Use two unique patient identifiers at point of sale



Quick Check Question: Patient Information

- 1. Other than patient age and allergy information, what key piece(s) of information should be documented when filling a prescription for a pediatric patient?
 - A. Indication for prescription
 - B. Patient's current weight
 - C. Co-morbid conditions
 - D. All of the above

Answer: D. All of these are key pieces of patient information needed to properly screen a prescription for appropriateness and safety. Obtaining the patient's weight is crucial when filling pediatric prescriptions because most drugs are dosed based on weight. Also having the knowledge of what the physician is treating will allow determination of whether or not the dose is within an acceptable range. Co-morbid conditions, such as renal failure, will also aid in determining the appropriateness of the dose.



Key Element II: Drug Information

Essential drug information is readily available in useful form and considered when dispensing medications. Practitioners are familiar with or are able to review, prior to dispensing, information about the product's known risks and hazards.

Background

Research demonstrates that more than one-third (35%) of all preventable adverse drug events (ADEs) are directly related to inadequate dissemination of drug information.⁴ Overall lack of knowledge about drug therapy was the most common cause of medication errors during both drug prescribing and drug administration, with dosing errors occurring most frequently. One in six ADEs were caused by the combination of insufficient knowledge about usual drug doses with miscalculations or incorrect expression of measurement or drug concentration.⁵ The wrong dose and wrong drug choice were most likely to cause serious injury to patients.

Errors with Drug Information causative factors

Example II-1: An error which could have resulted in a significant, harm-causing opioid overdose was reported. The prescriber added "IR" (to indicate immediate release) to an order for OPANA (oxymorphone). The pharmacist interpreted the "IR" to be "ER," the common suffix used to indicate the extended release product.

Recommendations

Example II-1: Prescribers should use a suffix to differentiate a product only when this designation is linked to a specific product and represents the FDA-approved name for the prescribed agent. When confronted with a non-standard or unrecognizable suffix, pharmacists should verify the intended product and dose with the prescriber.

Errors with Drug Information causative factors

Example II-2: A prescription for SINEQUAN (doxepin) 10 mg, with the directions to take 5 capsules daily, was mistakenly entered into the computer and dispensed as Sinequan 100 mg. Upon entering "Sinequan" on the product line in the pharmacy software system, the list of matching results placed Sinequan 100 mg on the first line followed by Sinequan 10 mg. It's believed that the sequential listing of both strengths, with a tenfold difference, contributed to the selection of the wrong strength, as did the listing of the higher strength first.

Recommendations

Example II-2: Ask your pharmacy software vendor about the logic used by its system when sorting drug information (e.g., alphabetical vs. numerical listings). Until this issue can be resolved by software vendors, consider adding an asterisk to the doxepin 100 mg strength name (doxepin *100 mg) to cause it to fall to the bottom of the alphabetical sort. However, this may not be a safe option if electronic



calculations of doses and dose limits originate with information in the field that contains the asterisk. In these cases, the asterisk may interrupt or alter the calculation process.

II. Common Contributing Factors Involving Drug Information

Outdated/absent references

Inaccessible or non-accessed drug references

Inadequate computer alerts for allergies, health conditions, minimum or maximum doses and non-pharmaceutical drug interactions

No internet access available to obtain current drug information for OTCs, herbals, and dietary supplements

Independent checks for high-alert drugs and high-risk patient populations not performed

Lack of staff awareness of special precautions on new medications

Computer warnings about unsafe doses overlooked or ignored

Serious drug interaction unknown or overlooked

Computer system provides too many alerts resulting in alert fatigue and automatic overrides by pharmacy staff

A drug information center staffed with clinical pharmacist is not available during all hours of operation

On-line, immediate clinical information is not available, accessible or appreciated by staff

II. Drug Information Suggested Risk Reduction Strategies

Quality Improvement Activities by Staff

Educate all staff, including technicians, about new drug products coming to market and/or being stocked in the pharmacy. See Figure II-1

A designated pharmacist or corporate level staff routinely reviews, for quality improvement purposes, reports of computer warnings that are overridden by pharmacists

Manually check the patient's profile during the DUR process, for medications and health conditions which may not be included in the DUR software

The most current electronic drug references are available in the pharmacy; all outdated paper references are thrown out or taken home by staff



II. Drug Information Suggested Risk Reduction Strategies

Provide pharmacy staff with access to drug information center staffed with clinical pharmacists during all hours of operation; alternately, provide up to date clinical information available via internet and/or printed material and ensure all pharmacists, interns, etc. are aware of the resources and trained in accessing and reviewing available drug information databases

Provide resources, time, and encouragement to staff to participate in MTMS

Review external error reports for potential risk within your own pharmacy

Technology Considerations

Provide easy access to online drug information at every computer terminal. Provide an easy access icon, so the link is readily accessible

Allow pharmacy staff the ability to enter, or request the addition of look- and soundalike and other targeted drug warnings into the pharmacy computer system

Configure the pharmacy computer system to offer alerts for maximum and minimum doses of medications, drug interactions, age, allergies and dose related interactions

Invest in a computer system that prompts DUR alerts for women of childbearing age when Category X drugs are being dispensed

Carefully select alert severity levels to avoid alert fatigue; consider refining the computer system to allow only clinically significant alerts to fire (Combine with above)

Evaluate how drug information appears on computer screen: do not use dangerous mnemonic speed codes i.e. 'novo7030' should not be a mnemonic speed code because it could be for NovoLIN 70 30 or NovoLOG 70 30; consider tall man lettering for look-alike drug names, such as hydrOXYzine and hydrALAzine; be aware of the number of characters that will appear on the screen before the drug identification is truncated

Routinely run report of system speed codes in use and review for dangerous short codes; use the ISMP commonly confused drug list for examples of drug product names that could lead to error, if codes can be interchanged, linking to unintended products.

Speed codes should only be added by administrative personnel using a standardized process, not at store level

Mandate a pharmacist review of clinically significant computer warnings and have the ability to trace and document all steps in the DUR process

Provide internet access for current information on OTC, herbal, and dietary supplements





Figure II-1 All of these bupropion products are not equivalent

Quick Check Question: Drug Information

- 1. Prescribers and pharmacists should review medication safety websites, newsletters, and look-alike/sound-alike (LASA) lists annually for potential drug confusion associated with the medications they use most frequently.
 - A. True
 - B. False

Answer: B. Pharmacists should be proactive and review external sources of medication safety information and LASA lists *more frequently* than once a year. Drug names can be cumbersome and confusing and look and sound like one another. This is a particular risk with new drugs, because it is more likely that pharmacists and technicians are unaware of the new drug. See Figure II-2. *Any time* a new drug is first dispensed, pharmacists should consider the potential for drug-drug interactions, duplication of therapy, and LASA name confusion. In addition, safety information should be reviewed and communicated to technicians.

Figure II-2 Lantus insulin order interpreted as Lente insulin by pharmacy staff unaware of new insulin type on formulary



Key Element III: Communication of Drug Orders and Other Drug Information

Methods of communicating prescription orders and other drug information are standardized and automated to minimize the risk for error.

Background

Miscommunication between physicians, pharmacists and nurses is a common cause of medication errors. Failure to control and standardize prescribing vocabulary often leads to inappropriate use of dangerous abbreviations, acronyms, coined names and other ambiguous methods of communicating drug information that can easily be misinterpreted. Studies have identified that greater than one in ten medication errors are directly related to the use of incorrect drug names, confusing expressions of dosage forms, and misunderstood abbreviations.⁵ The same study also identified that misinterpreting decimal point placement, often resulting in ten-fold overdoses, was one of the leading factors causing errors that could seriously harm patients.

Spoken orders, fraught with danger of being misheard, are another method of communicating orders that is often misinterpreted. While spoken orders may be convenient to those prescribing medications, their use should be reserved for true emergency situations, to minimize unnecessary obstacles to clear communication. When reducing telephone orders to writing, pharmacists should never abbreviate drug names or use dangerous abbreviations when transcribing the patient administration directions. See Figure III-1. Internal use of dangerous abbreviations and dosage forms can lead to misinterpretation by staff, and by patients if incorrectly translated onto prescription labels. Store-specific training guides and company policies should not allow nor promote the use of dangerous abbreviations. See Appendix 1 or www.ismp.org/Tools/errorproneabbreviations.pdf for a complete list of abbreviations that have been misunderstood and led to prescribing and dispensing errors.

FLOMAK D.Y.My PO QD

Figure III-1 "QD" for "daily" transcribed by pharmacist when taking spoken order entered as "QID" or four times a day by technician, due to inappropriate use of dangerous abbreviation and illegible handwriting.

There is also a significant problem of illegible handwriting. The current paper-based system for recording and communicating drug prescriptions in the United States is a poor medium of communication and is associated with inefficient workflows.⁶ MEDMARX[®] is a national, Internet-accessible database that hospitals and health care systems use to track and trend adverse drug reactions and medication errors. MEDMARX[®] data reports there are 1,470 different drugs implicated in medication



errors due to brand and/or generic names that looked or sounded alike. From this data, USP has compiled a list of 3,170 pairs of names that look and/or sound alike.

Errors are much more likely when handwriting is legible but conceals something that is dangerous. In many cases drug name mix-ups happen when the handwriting is legible but still makes one drug name look like another. While it may seem unlikely, a prescription for the antidiabetic agent AVANDIA (rosiglitazone) may be mistaken for the anticoagulant COUMADIN (warfarin) due to look-alike tendencies when handwritten in cursive.⁷ (Figure III-2).



Figure III-2 Handwritten "AVANDIA" can look surprisingly like "COUMADIN."

In order to prevent such errors, additional system enhancement steps must be incorporated; such as electronic prescribing, assuring the drug corresponds with therapy given for the patient's condition, patient counseling, etc.

Electronic prescribing, also known as e-prescribing, eliminates incorrect handwriting interpretation, and ensures that vital fields include meaningful and relevant data.¹ However, development and testing of e-prescribing standards have fallen short of ensuring transmission of error-free prescriptions.

Types of Errors Reported from Electronically Produced and Transmitted Prescriptions	Example
Missing or mismatched quantities	Prescriber selects quantity of "1" for 10 mL insulin vial
Mismatches between drug dose type ordered and dosage units ordered (solution ordered with quantity as tablets)	Prescriber selects Amoxicillin Suspension and selects quantity as 30 "tablets"
Wrong drug selected by prescriber due to "stemming" (i.e., enters first few letters of drug name) at order entry and subsequent incorrect selection	Prescriber enters "met" and then selects metoprolol tartrate (LOPRESSOR) instead of intended metoprolol succinate (TOPROL XL)
Wrong drug selected from drop down menu of medications listed alphabetically	Prescriber selected procarbazine from drop down menu of medications, but intended to prescribe PROCARDIA



Types of Errors Reported from Electronically Produced and Transmitted Prescriptions	Example
Wrong drug selected because entire medication name not visible on selection screen, and prescriber does not scroll field to read entire drug name being ordered	Prescriber chooses "Met FORMIN 500 mg" tablets, but intended "Met FORMIN 500 mg ER"
Instructions sent in the <i>SIG</i> field contradict what is sent in the notes field	"Take 1 tablet twice a day" in <i>SIG</i> , but the notes field states "Take 1 tablet in the morning and 2 tablets at bedtime"

Patient instructions for taking medications are called the *signatura*, commonly abbreviated *SIG*. Currently, there is no standardized format for vocabulary for *SIG*s. Mistranslations and contradictions in dosage/timing directions leave room for misinterpretation and error.⁸ See Figure III-7 for an example of complications from an electronically generated prescription, which could result in administration errors.

In all healthcare settings, communication barriers, such as intimidation, often precipitate ineffective communication between health care professionals. In a recent ISMP survey on workplace intimidation, 40% of the respondents reported they had questions about the safety of an order in the past year but chose to assume the order was correct rather than interact with a prescriber they perceived as intimidating.⁹ Any questionable prescription should be discussed directly with the prescriber. A pharmacist's persistence in communicating recognized problems, even when met with opposition from experts, can clearly prevent harmful errors from reaching patients. If applicable, the pharmacist should ask the prescriber for documentation (e.g., protocols, journal articles) supporting the order and read any materials provided. The prescriber may have misinterpreted published information or used references that contain misprints.

Errors with Communication causative factors

Example III-1: A physician wrote a prescription for lamo**TRI** gine 100 mg (see order #2 in Figure III-3). Subsequently, a pharmacist misread the handwritten order as levothyroxine 100 mcg. The drugs have overlapping dosage strength numbers (25, 100, 150, and 200) and are administered orally once daily, increasing the risk of mix-ups.





Figure III-3 Order #2 for lamoTRI gine was misinterpreted as levothyroxine

Recommendations

Example III-1: Warn practitioners about the potential for mix-ups with these products. Encourage prescribers to include the indication for use on prescriptions for these drugs, and write only one medication order per prescription blank. When receiving spoken orders for these medications, ask the prescriber or agent for the purpose and write it on the prescription pad. Pharmacists should always counsel patients on these medications (new and refill) to help avoid mix-ups; the prescription may have originally been filled correctly, yet still misread and picked incorrectly on refills.

Errors with Communication causative factors

Example III-2: A pregnant patient had been given a prescription for "PNV" tablets ("prenatal vitamins"). The pharmacist receiving the prescription assumed that PNV stood for "penicillin VK" and dispensed penicillin tablets in error.

Recommendations

Example III-2: Abbreviating drug names is an unsafe practice that should be avoided. Prescribers should never use them, and pharmacists should always check with prescribers as to the intended meaning of any drug name abbreviation.

Errors with Communication causative factors

Example III-3: During a patient counseling session, a pharmacist realized that he had nearly dispensed PROGRAF (tacrolimus) instead of **PRO**zac (fluoxetine). Sound-alike drug names communicated over the telephone, without any opportunity to read back, contributed to the near-miss.

Recommendations

Example III-3: Repeating and verifying drug information communicated by telephone may help prevent this type of error. Pharmacies which use prescriber voicemails to leave oral prescriptions should consider utilizing a second person to listen to spoken orders left on the Integrated Voice Response (IVR) system. Patient counseling sessions that include reviewing the indication for therapy and the prescribed medication give pharmacists the opportunity to catch errors before harm occurs.



III. Common Contributing Factors Involving Communication

Ambiguous directions

Poor handwriting; see Figure III-4

Misread prescription; see Figure III-5

Oral Rx misheard, see below: "Avinza 60 mg daily" misheard as: "Evista 60 mg daily"

Typing mistake (incorrect data entry code or mnemonic)

Poor fax quality; see Figure III-6

Incomplete e-Rx

Ambiguous e-Rx; see Figure III-7

Prescriber error

Use of previous drug/dose on profile

Wrong drug, wrong dose, wrong route

Use of error-prone *sig* and drug name abbreviations or dosage designations; see Figure III-8

Intimidation/faulty interaction with prescriber or agent

Unable to clarify with physician

No policy on how to resolve conflicts on potentially unsafe prescription orders

Rx Prusmint Jomy

Figure III-4 Written as PREVACID, interpreted and filled as PRINIVIL



DProc XC to Times in

Figure III-5 Interpreted and dispensed as Toprol XL 50 mg; written as "decrease Toprol XL to 12.5 mg each day"



Figure III-6 Written for 40 mg, dispensed as 10 mg due to fax "noise" (i.e., vertical line)

R TOBRADEX OPTH SUSPENSION 1 DROP OD QID Dispense: 1-Bottle(s) Special-Instructions 3 DROPS IN LEFT EAR TID X DAYS PER AT Meel OK PER MD Relik

Figure III-7 *SIG* and special instructions indicated conflicting patient administration instructions

60 Regular INSULIN

Figure III-8 Inappropriate use of "U" for units. "6 units" confused and entered as "60 units" and led to a ten-fold overdose

III. Communication Suggested Risk Reduction Strategies

Onsite Staff Implementation

Incorporate mandatory read back procedures when accepting spoken prescription orders to confirm understanding; incorporate patient validation and second patient identifier with prescriber or agent

Repeat numbers in digits when receiving oral prescription orders (16 is stated "onesix", 60 is stated "six-zero")



III. Communication Suggested Risk Reduction Strategies

Spell sound-alike drug names back to caller and obtain indication for use from caller for sound-alike medications

Immediately call prescribers when prescriptions are written illegibly or ambiguously; do not fill the prescription until the order is confirmed

Inform prescribers when eRxs are continuously received with ambiguous patient directions (contain both a *sig* and *special instructions* which may conflict)

Maintain fax equipment to ensure clear images: educate users about potential errors with margins, numbering, etc.

Instruct staff never to use error-prone abbreviations or error-prone dose designations (trailing zeros and lack of leading zeros), drug name abbreviations or abbreviated *sig* codes when reducing oral prescriptions to writing; prohibit the use of dangerous abbreviations and dose expressions on patient prescription labels

Prohibit staff from coining abbreviations for drug names or entering new *sig* or speed codes

Establish procedures that specify the steps that should be taken when there is question as to the safety of a prescription order

Prohibit the use of dangerous mnemonics and stemming during data entry; to avoid product selection errors if mnemonics are allowed and used, consider programming computer entry screens to display the specific brand names along with the generic names whenever a stem or mnemonic is entered or apply tall man lettering to the drug names on the selection screen

Corporate/Owner Action

Incorporate IVR systems that have hard prompts to require the physician or agent to stop and spell all names (prescriber, patient, drug, strength) when leaving a spoken prescription order

Use prescription phone pads that prompt receiver to ask caller for allergies, date of birth, and indication for use or purpose of drug

Implement a true electronic transmission system with minimum data entry/transcription required

Evaluate sig codes and speed codes for error potential

Incorporate the use of scanning procedures so that original prescriptions can be viewed during each refill process

Ensure adequate fax scanning technology equipment and procedures



Quick Check Question: Communication

- 1. Which is NOT an appropriate way of preventing medication errors associated with spoken orders?
 - A. Read back order
 - B. Spell drug names back to caller
 - C. Use abbreviations
 - D. Obtain indication for therapy

Answer: C. Although prescribers often speak much faster than one can write, it is important to avoid using error-prone abbreviations and dose designations. In many pharmacies, the hard copy of the prescription is scanned into the pharmacy computer system. This image is then used during final verification. Error-prone abbreviations used on the prescription can be misinterpreted by a different pharmacist, which may result in an error. Therefore, it is important not to use abbreviations and clearly write out complete drug names and directions for use.

Telephone orders should be immediately written on a blank prescription pad or electronically documented. Require staff to perform a read back of the medication name, strength, dose, and frequency of administration for verification, to avoid misinterpretation. This step is absolutely essential and should become a habit, even if the recipient is confident that he or she has heard the order correctly. As an extra check, either the prescriber or recipient should spell out unfamiliar drug names, using "T as in Tom," "C as in Charlie," and so forth. Pronounce each numerical digit separately, for example, "one six" instead of "sixteen" to avoid confusion with "sixty." Have a second person listen to the order. This should be a requirement if the recipient is inexperienced. Obtain the purpose of the prescribed medication to ensure that the order makes sense in the context of the patient's condition. Most reported sound-alike name pairs have different indications. The recipient should note the date, time, and name of the caller on the prescription when it is received.



Key Element IV: Drug Labeling, Packaging, and Nomenclature

Strategies are undertaken to minimize the possibility of errors with drug products that have similar or confusing manufacturer labeling/packaging and/or drug names that look and/or sound alike.

Prescription labels clearly identify the patient, product, directions for use, the dispensing pharmacy, and any other important information that the patient may need to take the medication accurately and safely.

Background

Drug names that look and sound alike, confusing or absent drug labeling, and nondistinct or ambiguous drug packaging significantly contribute to medication errors. These conditions have led to serious drug mix-ups and deaths. Research has identified that one of the most frequent causes of pharmacy drug dispensing errors (29%) is failure to accurately identify drugs, most prominently due to look-alike and sound-alike drug names.⁴

Many medications are packaged in bottles with similar shapes and similar labels, making it easy to confuse one drug with another. See Figure IV-1.



Figure IV-1 Similar looking drug bottles are easily confused.

The problem is aggravated by what is referred to as *confirmation bias*: when choosing an item or verifying a name, you see what you are looking for, and once you find what you are looking for, you stop looking, not recognizing any disconfirming evidence. Often pharmacy staff chooses a medication container based on a mental picture of the item, whether it is a characteristic of the drug label, the



shape and size or color of the container, or the location of the item on a shelf.¹⁰ Many errors often occur when practitioners, due to familiarity with certain products, see what they think is correct rather than what is really there. It is human nature for people to associate items by certain characteristics.¹¹ Physically separating drugs with look-alike labels and packaging helps to reduce this contributing factor.¹²

Changing a product's name or appearance may help prevent LASA medication errors. For example, tall man (mixed case) letters call attention to a drug's name and distinguish it from its LASA name pair. Several studies have shown that highlighting sections of drug names using tall man letters can help distinguish similar drug names,¹³ making them less prone to mix-ups.^{14,15} ISMP, FDA, The Joint Commission, and other safety-conscious organizations have promoted the use of tall man letters as one means of reducing confusion between similar drug names. In fact, the FDA has compiled a list of look-alike drug name pairs in which tall man lettering is recommended. One such name pair is diphenhydramine and dimenhydrinate. According to FDA's tall man lettering scheme, diphenhydramine would be presented as diphenhydr**AMINE**, whereas dimenhydrinate would be dimenhy**DRINATE** (see Figure IV-2). The unique letter characters in look-alike drug name pairs may also be highlighted using color, reverse color background, italics, underline, and other distinguishing delineations.



Figure IV-2 "Tall man" letters and reverse color background help distinguish one drug from another.

With FDA approval, other manufacturers have employed tall man lettering schemes to differentiate look-alike brand names when medication errors were recognized post-market. For example, Eli Lilly uses reverse-color background, italics, and tall man lettering to help differentiate Zy**PREXA** from Zyr**TEC**. See Figure IV-3.







Figure IV-3 Former ZyPREXA label (left) next to ZyrTEC label. New ZyPREXA label (right).

One of the difficulties with the use of tall man letters is the lack of scientific evidence regarding which name pairs would most benefit from this error-reduction strategy as well as which letters to present in uppercase. To help promote standardization, ISMP suggests that the tall man lettering scheme provided by FDA and ISMP for the drug name pairs listed in Appendix 2 be followed consistently. This list can also be found at www.ismp.org/tools/tallmanletters.pdf.

Error with Drug Labeling, Packaging, and Nomenclature causative factors

Two formulations of BYETTA (exenatide) are distributed in pen injectors (Figure IV-4), one delivering 5 mcg/injection and one delivering 10 mcg/injection. The wrong strength may be dispensed because both pens have similar NDC numbers. The middle four numbers, which usually represent the distinct drug product, are actually the same for both strengths of the BYETTA pen. Only the final two digits of the NDC numbers are different which may not be read by certain barcode scanning programs.



Figure IV-4 The two Byetta pens deliver different doses.



Recommendations

Manual double-checks of BYETTA products, to include the entire NDC number, are warranted to ensure the correct strength is dispensed, especially in community settings where erroneous dispensing could lead to repeated dosing errors.

IV. Common Contributing Factors Involving Drug Labeling, Packaging, and Nomenclature			
Look/sound-alike names and mnemonics			
Look-alike packaging; see Figures IV-5, IV-6, IV-7			
Generics manufactured by one company using similar packaging and labeling throughout product line; see Figure IV-8			
Unclear/absent labeling			
Faulty drug identification (no drug image, drug image not updated, selection not verified by NDC or bar-coding)			
Branded/generic drug name confusion			
Lack of special precaution labels on high-alert medications			
Labels on wrong vials but for right person (swapped)			
Directions on patient label not easily understood (e.g., 1 1/2)			
Correctly typed labels put on different person's prescription			
Confusing, incorrect or misunderstood auxiliary labels on patient vials			



Figure IV-5 Very little differentiation within product line





Figure IV-6 Look-alike packaging



Figure IV-7 Internal use and "external use only" products packaged in look-alike bottles



Figure IV-8 Generic line by Teva has look-alike labeling for manufacturer recognition, but non-differentiation of labels can lead to selection errors



IV. *Drug Labeling, Packaging, and Nomenclature* Suggested Risk Reduction Strategies

Onsite Staff Implementation

Include the purpose of the medication on the patient's prescription label, if provided by the prescriber

Provide auxiliary warning labels with exaggerated fonts, or use other label enhancements on packages and storage bins of drugs with problematic names, packages, and labels; see Figure IV-9

Use shelf dividers to separate products with look-alike names/packaging in all storage areas, including refrigerators and narcotic cabinets; see Figure IV-10

When drugs have the same name but different routes of administration (e.g., ophthalmic vs. otic), steps are taken (e.g., auxiliary labels, change in storage location, purchase from different manufacturer, notation in the computer, etc.) to prevent dispensing errors

When dispensing unit-of-use packaging to patients, avoid placing pharmacy label on top of pertinent manufacturer's information

Prescriptions are dispensed using the original prescription order and the computergenerated drug label together; a pharmacist compares the label and product with the original prescription before drugs are dispensed to the patient

Corporate/Owner Action

When possible, avoid stocking generic manufacturers who incorporate same size stock bottle, and label colors and fonts, in their complete product line

Avoid stocking branded generic drug products

Use labels with special precautions on the stock bottles of high-alert medications (those whose inadvertent dispensing could cause serious harm if used in error)

Design prescription labels for patients that are easy to read, have enough "white" space, have a font size that is legible to older patients, and which contain the proper information for safe drug administration; refer to ISMP website for specific label guidelines <u>www.ismp.org/Tools/guidelines/labelFormats/comments/default.asp</u>

Perform Failure Mode and Effects Analysis (FMEA) on packaging and labeling of new drugs being considered for addition to pharmacy stock

Use FDA/ISMP-recommended tall man lettering on repackaged products

Identify stock bottle labels that are ambiguous or unsafe, and contact manufacturer or discontinue stocking from this manufacturer if safety features cannot be adequately employed; in addition, report these hazardous labels to ISMP

Regularly review current external literature for noted problems with drug labeling, packaging and nomenclature; and incorporate actions to prevent errors stemming from these issues



IV. *Drug Labeling, Packaging, and Nomenclature* Suggested Risk Reduction Strategies

Technology to Consider

Implement bar-coding technology for the verification process of drug selection; provide and train staff on policies and procedures to be implemented when stock product does not have a barcode or has a barcode that is not readable

Implement tablet imaging on final verification screen; see Figures IV-11, IV-12, IV-13

The pharmacy computer system produces clear and distinctive labels that are free of abbreviations or dose expressions that may not be easily understood by a patient

Use a pharmacy computer system that employs up-to-date drug/pill imaging technology during the checking process

Employ a pharmacy system which allows alerts to be built in, as necessary, regarding problematic drug packaging; see Figure IV-14

When applicable, print patient prescription label in patient's language

A system that compares computer-generated NDC codes on prescription labels and NDC codes on manufacturers' containers is employed to verify that the appropriate drug has been selected and dispensed

Prem PHASE0.625mg/5mg -2570-PREMpro 0.625mg/2.5mg -2572-

PREMPRO 0.625mg/5mg

-0975-

Figure IV-9 Examples of store-made shelf labels used to differentiate product on stock shelves





Figure IV-10 Shelf dividers (left); refrigerator bin with plastic dividers between rows of look-alike manufacturer labeled product (right)

	Descent of the second s	
them together manufacture	a tarta bases based a tarta based based	a beligera
		ELEFE
A Departure A Dep	N. M. The second	重加推制
A DECK	a to the second se	

Figure IV-11 Image of medication selected at data entry is shown at final verification stage



Figure IV-12 Image can be enlarged on computer screen; both front and back are depicted with the narrative description "This medicine is a PINK, ROUND-shaped TAB imprinted with COUMADIN 1."





Figure IV-13 Image can be enlarged on computer screen; both front and back are depicted with the narrative description "Front: Corgard 40 mg , Back: BL/207."



Figure IV-14 Depicts pharmacy computer system with tablet image and special alerts for medication being dispensed

Quick Check Question: Drug Labeling, Packaging, and Nomenclature

- 1. All of the following techniques may help prevent a mix-up between diphenhydramine and dimenhydrinate EXCEPT?
 - A. Computer alerts that warn for the potential LASA mix-up
 - B. Use of tall man letters on drug selection and verification screens
 - C. Using a bar-code scanning system to identify the drug
 - D. Storing bottles on a fast rack section where there is better lighting
 - E. All of the above are acceptable

Answer: D. Perhaps there is better lighting in the fast rack section, but these two drugs could potentially still be next to each other on the shelf. By physically separating the two medications, this will help to reduce the contributing factor for error.



Key Element V: Drug Standardization, Storage, and Distribution

Prescribed medications are accessible to patients and dispensed in a safe and secure manner. Medications and other necessary drug supplies are stored, dispensed, and returned to stock in a manner that reduces the likelihood of an error.

Hazardous drugs and chemicals are safely sequestered and accessible in drug product preparation areas.

Background

All areas of storage including shelves, refrigerators, narcotic safes and will-call bins should be of adequate size to avoid clutter. Recommendations include having separate glass-front refrigerators for stock and filled prescriptions, and narcotic safes or cabinets that are of adequate size to meet the needs of the particular pharmacy. Both refrigerators and safes should have shelf dividers or baskets that allow for well-spaced stock that can easily be seen. Never allow employees to store food in any refrigerator used to store medications. Past error reports indicate one pharmacy mistaking a dangerous refrigerated chemical for drinking water, and subsequent accidental ingestion of that chemical.

Each pharmacy should develop a process to regularly review stock for short-dated products that need to be removed from active inventory. Expired, returned, and recalled medications waiting return to wholesaler or manufacturer, need to be stored in areas clearly differentiated from regular stock.

Separation of regular stock needs careful consideration. Cluttered shelf stock and drawers increase the possibility of picking errors. Recommendations include the use of cost-effective shelf dividers and sloping pull-out drawers to enable stock to be easily seen and retrieved. Sloping pull-out drawers should be considered for smaller items such as eye drops and eye ointments.

If adequate space for receiving and checking in new stock does not exist, there is a greater chance medication will be incorrectly slotted on the stock shelves. Since people are wired for automaticity in stock retrieval, there is a greater chance for product mis-selection when stock is placed in the wrong spot. Unopened or partially opened tote boxes of replacement stock on the pharmacy floor are both a distraction and a hazard. A dedicated bench for unpacking and checking stock is recommended to reduce the potential for product mix-ups. Technology which allows for automatic stock replenishment without the need to check off incoming stock should be considered as a future enhancement.



A simple, consistent alphabetical system is easy for all staff to use for both stocking and retrieval of product. Recommendations include a straightforward A-Z stock storage system by proprietary or generic name with no regard for dosage type, i.e., inhalers, birth-control packages, topicals, liquids, etc., intermixed with tablets and capsules. Medications with more than one active ingredient should be stocked alphabetically by the first product that would appear on the computer generated label. Care should be given to look- and sound-alike names and packaging, with known problematic drug pairs being sufficiently separated, regardless of normal alphabetical placement. Staff should be informed as to the safety motive for these "mis-alphabetized" items. Shelf-talkers that note a different strength is available and where it is located in the pharmacy would be helpful and promote safety. A simple statement such as "another strength available" is advisable, since specifying "concentrated strength" or listing the actual strength of the moved product could cause staff to identify the information on the shelf-talker with the product in the bin above the shelf-talker.

Error with *Drug Standardization*, *Storage*, *and Distribution* causative factors

An error was reported in which methylphenidate 5mg was dispensed instead of oxy**CODONE** 5mg. The error was due to look-alike container labels from the same manufacturer being misread. (see Figure V-1)



Figure V-1 Both products manufactured by Mallinkrodt, bearing same pink label with CII prominent in upper right corner

In addition, both drugs are schedule II and stored next to each other in a crowded narcotic cabinet. The staff had put the strength of the tablet on the top of the vial container for easier retrieval. In this case, both stock bottles had the number "5" handwritten on them. See Figure V-2.





Figure V-2 Crowded narcotic cabinet

Recommendations

Store the containers of these products apart from one another; add reminders to stock bottles and computer screens about the potential for error.

V. Common Contributing Factors Involving Drug Standardization, Storage, and Distribution			
Picked next drug on shelf			
Drug stocked incorrectly			
No shelf dividers used on crowded shelves; see Figure V-3			
No dividers used to separate sound- or look-alike products; see Figure V-4			
Ophthalmic and otic products stored next to each other without warning labels or dividers			
Stock drugs and filled prescriptions stored in same refrigerator			
Disorganized and unlabeled refrigerator storage			
Crowded will-call/pick up area; see Figure V-5			
Filled prescriptions not returned to stock in timely manner			
Recalled and discontinued drugs not segregated from active stock			
" <u>Basket</u> " system not used (or inadequate size baskets used) to separate patient orders; see Figure V-6			



V. Common Contributing Factors Involving *Drug Standardization*, *Storage*, *and Distribution*

Inadequate double-checks when restocking automated dispensing units

High-alert and look- and sound-alike medications stocked in "fast mover" section

No signage used for high-alert or look-alike drug products

Reconstitution and compounding ingredients stored in close proximity



Figure V-3 Crowded, haphazardly stocked shelves; products not oriented for viewing label



Figure V-4 Crowded shelves; no dividers between similar packages; products not oriented for viewing label contents





Figure V-5 Crowded will-call area can lead to wrong bag/receipt being selected



Figure V-6 Lack of separation of patient orders can lead to mislabeling vials

V. *Drug Standardization, Storage, & Distribution* Suggested Risk Reduction Strategies

Onsite Staff Implementation

Implement a stocking program which completely separates ophthalmic and otic products that have been reported as being confused for one another

Institute a "shelf talker" or signing program that brings attention to sound- and lookalike drug products during stocking and retrieval procedures; see Figure V-7

Eliminate from storage potentially dangerous chemicals no longer necessary for compounding

Do not store non-drug supplies, such as alcohol, near diluents and products that require reconstitution

Immediately remove from current inventory outdated, recalled and discontinued drug products, and secure away from current stock

Store in separate bins in the refrigerator different types of insulin and other similar items


V. *Drug Standardization, Storage, & Distribution* Suggested Risk Reduction Strategies

Never stock any part of a product line of a sound- or look-alike drug in the "fast mover" section (unless automation is employed)

Never place stickers or cross-out lines, which would obliterate key information, on any part of the stock bottle label

All stock, including return-to-stock vials, are always labeled with drug name, strength, expiration date, and NDC number or bar coding if possible

Never leave medication unlabeled (including blister packages) for any length of time

Utilize dividers on crowded stock shelves, in narcotic cabinets and in the refrigerators as needed; see Figure V-8

Always stock product with manufacturer label showing (never place product face down due to crowding on shelves)

Utilize adjustable shelving to fit height of product

Maintain a prescription pick-up/will-call area that is free from clutter, and contains enough space to prevent "spillage" into the next basket or bin

Institute "Return to Stock" procedures that include contacting the patient to pick up filled prescription, and subsequently within seven days, physically removing filled prescriptions not picked up or no longer wanted by patient

Corporate/Owner Action

Maintain temperature-alarmed, well-lighted, organized and shelf-labeled refrigerators of adequate size with bins or shelf dividers, as needed

Maintain separate refrigerators for stock and prepared prescriptions waiting to be dispensed to the patient

Consider implementing an automated dispensing system that incorporates robotics and/or bar-code verification systems to support the dispensing system in the pharmacy

Implement computer graphics (pill imaging) on the verification screen with each prescription, to show the appearance of the product, to guide selection of the proper drug

Institute procedures that allow only the verifying pharmacist to "bag" the filled prescriptions

Implement and distribute procedures to be followed in manufacturer out-of-stock situations

Institute policies and procedures to notify affected patients of manufacturer recall situations





Figure V-7 Example of tag that can be placed on shelf where known look-alike products are stored near one another



Figure V-8 Narcotic safe with pull-out drawers and adjustable plastic dividers

Quick Check Question: Drug Standardization, Storage, and Distribution

- 1. Which of the following are ways to prevent medication errors associated with drug standardization, storage, and distribution?
 - I. Use shelf dividers to separate all medications
 - II. Incorporate alerts in your pharmacy computer system for medications that have caused errors in your pharmacy
 - III.Store look-alike medications in fast mover section
 - A. I only
 - B. III only
 - C. I and II
 - D. II and III
 - E. I, II and III



Answer: C. It is important to always separate each medication in stock and never place multiple different medications in the same shelf bins. Adding alerts for problem LASA medications in your computer system is another way to help prevent errors. The alert may say "obtain or check indication", "this drug has been confused with . . .", or some other wording to alert technicians and pharmacists to an error that may be frequent. Storing look-alike medications in the fast mover section does not solve the problem. Even though the products would be in the fast mover section, there is still potential that the drugs would be stored next to each other.



Key Element VI: Medication Device Acquisition, Use, and Monitoring

The potential for human error is mitigated through careful procurement, maintenance, use, and standardization of devices used to prepare and deliver medications.

Sanitary practices are followed when using devices and equipment to store and prepare medications.

Background

Appropriate safety assessment of drug delivery devices prior to their purchase and during their use is key to safe medication administration. Competency in using drug delivery devices is paramount. For example, error reports from ISMP MERP indicate that a frequent cause of medication errors during drug administration is unfamiliarity with devices by both healthcare professionals and patients. When the variety and type of drug delivery devices are kept to a minimum, it is easier for staff to maintain the necessary expertise to safely administer medications. However, as new devices come to the market, it is essential that training tools for proper use and potential hazards be available to the trainers and to the patients.

Errors with *Medication Device Acquisition, Use, and Monitoring* causative factors

Example VI-1: ISMP has received reports of medication errors that have occurred when using pen injectors. Problems reported with the devices include error-prone device design, dispensing errors due to look-alike names, and mistaking multi-dose devices as single dose.

Recommendations

Example VI-1: Patient education with face to face counseling and actual demonstration of the device is crucial when prescribing or dispensing pen injectors. Some injectors come with a "demo" device for the patient to practice correct technique. Pharmacies should make sure they have "demo" devices to use for patient training.

Error-prone device design:



Figure VI-1 Pen is marked in mL but the drug is actually dosed in mg





Figure VI-2 The black end (left) shields the needle. The grey safety cap (right) must be removed before use – not an intuitive design for patients



Figure VI-3 Notation that the pen contains a 28-day supply is small and has been overlooked resulting in the entire contents being delivered as a single dose

Errors with *Medication Device Acquisition, Use, and Monitoring* causative factors

Example VI-2: A mother discovered she had been incorrectly measuring her child's dose of ranitidine syrup. The mother had been given a MONOJECT oral syringe (Tyco/Kendall) with metric and apothecary (minim) scales and had been measuring 3.5 minims (0.22 mL) using the apothecary scale on the syringe, rather than the correct dose of 3.5 mL.

Recommendations

Example VI-2: Tyco/Kendall has agreed to remove the minim scale from any syringes where it remains. They are also removing a terminal zero (1.0) on the syringe's metric scale. Pharmacists should provide a hands-on demonstration of how to measure liquid doses and require a return demonstration by the patient to ensure understanding of proper use of oral syringes.

VI. Common Contributing Factors Involving *Medication Device Acquisition, Use, and Monitoring*

Measuring device not dispensed with oral liquid medication

Automated dispensing devices not calibrated, maintained or cleaned

Compounding equipment not cleaned after use, resulting in next compounded product being contaminated or adulterated

Written instructions from manufacturer to patient/user limited or incomplete

Samples of devices not available for pharmacists to use for patient education during counseling sessions



VI. *Medication Device Acquisition, Use, and Monitoring* Suggested Risk Reduction Strategies

Onsite Staff Implementation

Using the "teach back" method, teach patients how to use measurement and monitoring devices

Perform manufacturers' suggested maintenance, calibration and cleaning schedules on all automated dispensing devices

Ensure newly cleaned equipment and measuring devices are used for each compound

Staff members use gloves or proper hand washing when handling individual loose oral solid products (e.g., capsules, tablets, etc.)

Staff members use appropriate hand washing procedures prior to compounding any prescription products (e.g., liquids, ointments, capsules, etc.)

Dispensing devices (e.g., counting trays, mortar and pestle, etc.) are washed after being used to prepare chemotherapy, penicillin, sulfonamide, opiate, or NSAID prescriptions

Only clean (washed) measuring devices are used for compounding liquids, ointments and capsules

Corporate/Owner Action

Institute policy to dispense all oral solutions with appropriate measuring device

Perform failure mode and effects analysis (see glossary, FMEA) on all automated dispensing devices and computer systems before purchase or implementation

Institute hand washing policies prior to and during shifts as needed

Obtain sample devices from manufacturers to be used for patient education/demonstration

Quick Check Question: Medication Device Acquisition, Use, and Monitoring

1. Pen injectors that deliver medication in specified doses are error-proof.

- A. True
- B. False

Answer: B. Pen injectors that deliver medication in specified doses are far from error-proof. The wide variety of pen injector designs makes it difficult for healthcare practitioners to learn how to use them properly and maintain competency. In fact, there have been many medication error reports describing misuse of pen injectors. For example, unintentional epinephrine injections from epinephrine pen injectors have occurred many times in patients, health care



professionals, and innocent bystanders.¹⁶ Pharmacies should make sure they have "demo" devices to use for staff education and patient training, and, of course, any healthcare practitioner who is prescribing or dispensing these injectors should be familiar with their use. Providing patient education for all medical devices and utilizing the "teach back" method are ways to minimize the risk of error with these injectors.



Key Element VII: Environmental Factors, Workflow, and Staffing Patterns

Medications are prepared and dispensed in a safe and orderly physical space and in an environment that allows practitioners to remain focused on medication use without unnecessary distractions.

The process and flow of work have been designed to enhance safety and worker efficiency.

The complement of qualified, well-rested practitioners and supportive staff matches the workload without compromising patient safety. Minimum time limits for filling prescriptions and/or other services should not be imposed on pharmacists or staff.

Background

Environmental factors, such as poor lighting, cluttered work spaces, noise, interruptions, and non-stop pharmacy activity often contribute to medication errors when staff are unable to remain focused on the tasks involved with medication use. Studies have shown that when light intensity is increased, medication errors are reduced.¹⁷ Another study confirmed that simple slips due to inattention are responsible for 11% of prescribing errors, 12% of administration errors, and 73% of transcription errors.⁴ (see glossary for definitions of error types) The process of transcribing orders and order entry is particularly vulnerable to distractions in the environment, as pharmacy staff are frequently answering telephones and requests for information while carrying out these responsibilities.

Reduced staff levels and increased workload can contribute to errors. Poorly designed systems, processes and workflow often prevent corrections to these situations. Well constructed workflow patterns and processes can help to reduce the chance of errors. Inefficiencies in workflow are at the root of rework, interruptions, inadequate information and supervision, poor prioritization and unproductive time management. The result is often an environment fraught with error-prone, complex work processes that significantly increase the risk of errors. An uninterrupted and logical workflow will create an intuitive progression that will help to reduce the chance of errors resulting from unclear processes. Cushioned flooring helps to alleviate fatigue. Safety recommendations suggest working temperatures should be no less than 16°C, 61°F and medication should not be stored at temperatures greater than 25°C, 77°F. Consider non-white bench colors, such as cream or grey, which provide more contrast to labels, packaging and medications.¹²

For more information on environmental conditions see USP proposed general chapter 1066 "Physical Environments that Promote Safe Medication Use" at: www.usp.org/pdf/EN/USPNF/PF34(6)Combined.pdf.



Error with *Environmental Factors, Workflow, and Staffing Patterns* causative factors

A patient received, from a local pharmacy, generic BIAXIN tablets 500 mg for a UTI, with the directions to take two tablets once daily. The prescription was actually written for BIAXIN XL. A pharmacy technician performed the data entry and product selection; the checking pharmacist missed the error during verification. According to the patient, this pharmacy is part of a chain where the work environment is typically very high pressured and fast paced. It appeared to the patient that the pressure of the workload caused the pharmacist to perform the checking too hurriedly.

Recommendations

Even in fast paced environments, steps can be taken to ensure adequate time for the verification process. Measures should include reducing clutter and crowding, matching workload with appropriate staffing levels, and improving lighting and technology so that errors can be "seen."

VII. Common Contributing Factors Involving Environmental Factors, Workflow, and Staffing Patterns

Inadequate lighting

Uncomfortable temperature

Excessive noise

Clutter and crowding

Interruptions

Workload inappropriate for staff

Inefficient workflow

Lack of consideration for employee safety; number and schedule of shifts worked not considered when creating work schedule

Meal breaks not scheduled or taken

Floater (substitute staff) unfamiliar with practice site

Lack of staffing contingency plans to cover illnesses and vacations, resulting in short staffing

Older technology not replaced

Managers not considerate of human factors when scheduling



VII. Common Contributing Factors Involving Environmental Factors, Workflow, and Staffing Patterns

Phone headsets missing volume adjustment

Staff not healthy or working when ill

Staff issues of visual acuity or hearing impairment

VII. *Environmental Factors, Workflow, and Staffing Patterns* Suggested Risk Reduction Strategies

Onsite Staff Implementation

Clearly identify workflow patterns that prevent overlap and crossover

Identify and reconfigure workstations which are adequately spaced to avoid crossover foot traffic

Avoid storage that requires staff to reach over their heads or to climb up to retrieve products

When creating the work schedule, consideration is given to the use of supportive dispensing technology and prescription volume, and pharmacist/technician ratios are ideally suited to minimize dispensing errors

Maintain workstations that are free of clutter

Identify high-risk situations, such as pediatric dose calculations, or areas of vulnerability that will require a double-check as a redundancy

Use devices that allow prescriptions to be read at eye level when being entered in computer

Utilize phone headsets which have adjustable volume control

Utilize the "<u>basket</u>" or other system to keep patient orders separate from each other during the dispensing process

Corporate/Owner Action

Consider ergonomics of work area to include: use of fatigue mats, and placement of vials, caps, phones, monitors, and trash receptacles

Control climate temperature and humidity for staff comfort and to conform to drug storage requirements

Utilize adjustable computer screens for staff comfort and safety, and to prevent glare

Establish a realistic staffing plan taking into consideration staff vacations, illnesses and meal breaks

Periodically examine prescription volume data to determine appropriate staffing levels, even during peak times when demand is highest



VII. *Environmental Factors, Workflow, and Staffing Patterns* Suggested Risk Reduction Strategies

Encourage staff to plan for and take needed meal breaks

Utilize consistent floaters, familiar to and assigned to particular store locations and workstations

Ensure adequate space, storage and lighting (10,000 ft candles) in medication stock and dispensing areas

Provide verification workstations that are free of disruptions and distractions

Replace old technology with new and improved technology when available (flat screen monitors, laser printers, new automated counting devices)

Enhance the workflow; implement technology such as fax machines, voice mail, touch tone telephone prompts, and e-mail for patients to request refills; to minimize staff interruptions

Implement IVR systems that are integrated with the computer system, to streamline priority in processing new (IVR doctor calls) and refill (IVR patient calls) prescriptions

Recognize under-worked (bored) or overstressed employees may have increased vulnerability to error

Provide a staff educational program on stress management

Provide an employee assistance program and encourage participation, to help staff who are experiencing stress that may affect work performance

Consider using staff located outside the dispensing area to resolve third party and prior authorization issues

Provide confidential area for patient counseling and MTMS

Consider refill reminder programs that automatically prioritize and refill patient prescriptions in a timely manner

Consider centralized filling processes and a common database to shift prescription filling to other locations

Encourage staff to have annual physicals to include visual and hearing screenings

Establish and publicize procedures to handle sudden staffing shortages due to illnesses and emergencies



Quick Check Question: Environmental Factors, Workflow, and Staffing Patterns

- 1. Under-worked staff may have an increased vulnerability to error.
 - A. True
 - B. False

Answer: A. It is often thought that only pharmacies with high workloads are error prone. However, under-worked staff also has a vulnerability to error. As reported in a study by Grasha, pharmacists were more vulnerable to mistakes under low workload conditions and when shifting from high to low activity. Boredom, reduced task focus, and disruptions in personal work rhythms made it hard to focus on tasks, even though pharmacists with both low and high workload were equally concerned about their performance and motivated to do well.¹⁸

- 2. Which of the following are risk reduction strategies that can be implemented to reduce errors associated with environmental factors?
 - I. To reduce clutter, place labeled vial on top of patient receipt, in a neat row, on dispensing counter for pharmacist to verify
 - II. Reconfigure work stations to prevent crossover foot traffic among staff
 - III. Store products in a way to limit excessive reaching and climbing on stools
 - A. I only
 - B. III only
 - C. I and II
 - D. II and III
 - E. I, II and III

Answer: D. Lining prescriptions up next to one another on the counter increases the risk of mix-ups and confusion. The use of a "basket" system should not depend on the volume of prescriptions being filled. This system allows for separation of each prescription order and reduces the chance of error. Unfortunately, in a community setting, it is difficult to predict when the volume will increase. Any situation can be managed by having routine strategies in place.



Key Element VIII: Staff Competency and Education

Practitioners and support staff receive sufficient training and orientation to the dispensing process and medication error prevention, and undergo baseline and annual evaluation of knowledge and skills related to safe medication practices.

Background

Staff education can be an important error prevention strategy when combined with other strategies that strengthen the medication-use system. However, it is a weak link with little leverage to prevent errors when attempting to use *only* this strategy for reducing errors. It is an impossible task to educate all practitioners about all things that they need to know to perform flawlessly when prescribing or dispensing medications. Thus, over the course of time, even the most educated, experienced, and careful healthcare professionals will make errors.

Staff education can effectively augment other error prevention strategies when it is focused on priority topics, such as the following:

- New medications being used in the pharmacy
- High-alert medications which have the greatest potential to cause patient harm if an error occurs, or drugs with unusual or critical dosing considerations
- Protocols, policies and procedures related to medication use, including those related to the use of drug delivery/administration devices
- Medication errors that have occurred within the organization or occurred in other organizations, and the error prevention strategies.

In addition, it is important to assess the baseline competency of all practitioners involved in the medication-use process. While demonstrating competence does not assure that errors will not occur, the process itself is educational and can help better prepare practitioners for safe medication practices. It can also help the organization develop an orientation program that meets the individual needs of all practitioners involved in the medication-use process. Adequate training and the ability to develop systematic procedures are essential to ensure that everyone conducts work in similar fashion.

Errors with Staff Competency and Education causative factors

Example VIII-1: When prescriptions for oral antibiotics requiring reconstitution are received by a pharmacy, the pharmacist often bags the patient-specific labeled medication with a "mix card" that informs the clerk that the medication requires mixing. Once the patient arrives at the pharmacy, the medication is reconstituted and dispensed. We received a report where a clerk gave an unmixed antibiotic to the patient's father who then accidentally measured 9 mL of *powder*, not 9 mL of liquid and administered it to his son.



Example VIII-2: An 8-month-old girl was prescribed amoxicillin/clavulanate potassium (AUGMENTIN) suspension to treat an ear infection. The prescription was taken to the family's local community pharmacy where a medication bottle labeled with the instructions to give the child a half teaspoonful twice daily was dispensed. When the family arrived home, they measured out a half teaspoonful of the *powder* and administered it to the girl. The pharmacy had failed to mix the powder with water prior to dispensing the medication. The girl was rushed to the emergency department where she recovered.

Recommendations

Examples VIII-1, VIII-2: Training and procedural issues should include consideration of placing new prescriptions for oral liquid medications, especially those that need to be reconstituted, in a separate area away from other prescriptions waiting to be picked up. Mark the area as "not to be dispensed without speaking to the pharmacist." This may help remind staff that the product needs to be mixed and that a pharmacist should review directions with the patient or caregiver. Other options include bagging in clear plastic bags, and inserting stops along the way at verification and at the cash register reminding of the need to mix. Include specific product descriptions on the prescription label (e.g., orangeflavored, white, thick liquid). Review the label and directions for use with the patient. Open the bottle with the patient and/or caregiver. Ensure that oral syringes (without caps) or other appropriate measuring devices are readily available with the product or for purchase at your practice site. Provide education to patients and caregivers regarding proper use of the measuring device. Have the caregiver or patient provide a return demonstration of how to measure and administer the dose. Inform caregivers how to clean the device, if it is to be reused.

Errors with Staff Competency and Education causative factors

Example VIII-3: Reliant Pharmaceuticals changed its brand name OMACOR (omega-3-acid ethyl esters) to LOVAZA to prevent confusion with AMICAR (aminocaproic acid) (see Figure VIII-1).

Coming this summer
The name OMACOR [®] (omega-3-acid ethyl esters)
LOVAZA
omega-3-acid ethyl esters
New Name, Same Medication

Figure VIII-1

A pharmacist who wasn't familiar with the new name misread a handwritten prescription for Lovaza 1 gram as **LOR** azepam 1 mg (see Figure VIII-2). Patient



counseling was offered when the prescription was picked up, but the patient declined. Fortunately, the patient discovered the error right away after reading the drug monograph at home. He returned to the pharmacy and was given the correct medication.

TUUNE

Figure VIII-2

Recommendations

Example VIII-3: One downside of changing the name of a well-known product like OMACOR is that it takes time before everyone becomes aware of the new name, just as it does with new products. Because of confirmation bias (seeing what is familiar while missing what is not), the possibility that the name will be misread increases during this "learning phase" if the new name is similar to another familiar product name. All staff and corporate personnel need to assure awareness of new product names and name changes, while promoting patient understanding about the importance of speaking to a pharmacist when medications are dispensed.

VIII. Common Contributing Factors Involving *Staff Competency and Education*

Insufficient competency validation

New or unfamiliar drugs/devices

Lack of orientation process; not trained for specific duties

No feedback about errors/prevention provided

Training on procedures and processes is insufficient

No training offered on how to handle or respond to medication errors

New drug information not communicated

Information regarding newly stocked drugs not communicated



VIII. Common Contributing Factors Involving *Staff Competency and Education*

Technician unfamiliar with prescription and OTC drug names

Previous internal and external errors and safety strategies not communicated

Continuing education not maintained

VIII. Staff Competency and Education Suggested Risk Reduction Strategies

Onsite Staff Implementation

Provide technician and pharmacist with on-the-job, side-by-side team training; and classroom training to meet the needs of the practice

Use technicians only in areas and for functions for which they have documented training

Arrange staffing so that trainers have reduced workload while performing on-the-job training

A supervisor evaluates each pharmacy staff member, at least annually, to assess his/her skills and knowledge related to safe medication practices

Pharmacists and technicians seek and receive ongoing information about medication errors occurring within the organization, error-prone situations, errors occurring in other pharmacies, and strategies to prevent such errors

Discuss potential medication errors and ways to avoid them during staff meetings

Encourage pharmacists to routinely provide technicians with new drug information, OTC medication information and recent Rx to OTC switches

When errors occur, offer education and suggestions to all staff, not just the staff directly involved in the error

Corporate/Owner Action

Provide practice site, competency-based orientation regarding stocking, dispensing, preparation, verifying and delivery procedures to all newly hired staff

Require staff scheduler to refer to documented levels of training before assigning tasks and shifts

Require minimum level of technician training before independent scheduling is initiated

Provide staff with on-line, readily accessible, current information about newly marketed or stocked drug products and devices to include guidelines, restrictions, and special precautions



VIII. *Staff Competency and Education* Suggested Risk Reduction Strategies

Provide staff with computerized timely updates on medications on back order or manufacturer mergers and any other pertinent "Inventory news"

Continually monitor corporate/owner training programs to include new tasks and procedures added to the dispensing process

Train staff and have policies and procedures in place on how to respond to internal medication errors

Provide staff with time and resources to attend educational programs related to medication use and error prevention

Pharmacy management supports educational programs for staff, such as live continuing education courses, professional meetings, journal club or in-services on new drugs and/or important drug safety issues

Evaluate each staff member's skills and knowledge regarding safe medication practices during annual employment review; address at-risk behaviors (see glossary) on an ongoing basis. Visit <u>www.justculture.org</u> for more information about this methodology

Provide pharmacists and technicians with a live educational program on ways to avoid errors with high-alert drugs, medications with a narrow therapeutic index, and other problem-prone products

When errors occur, educational efforts are widespread among all pharmacy personnel who may make a similar error, rather than remedial and directed at only those who were involved in an error

On an annual basis, provide staff with continuing education on internal and external reported medication errors, safety practices, high-alert medications, and strategies to reduce the potential for errors

Quick Check Question: Staff Competency and Education

- 1. When a medication error occurs, the most important step is to educate the person involved in the error.
 - A. True
 - B. False

Answer: B. Education of only the person involved with the error is considered a low leverage strategy to prevent error. (For more information on high and low leverage strategies, see Using the *Assess-ERR*[™] Tool in Community Pharmacy.) Staff education combined with higher leverage error-reduction strategies is a much more effective way to reduce medication errors. Staff competency should be assessed with regards to protocols, policies and procedures related to medication use,



including those related to the use of drug delivery/administration devices. Use tools such as the ISMP[®] Medication Safety Self Assessment[®] for Community/Ambulatory Pharmacy to gauge how well your pharmacy performs on key medication safety items.



Key Element IX: Patient Education

Patients are included as active partners in their care through education about their medications and ways to avert errors.

Pharmacists establish and participate in community-based disease prevention and monitoring programs to promote health and ensure appropriate therapy and outcomes of medication use.

Background

Patients should be advised that medication errors can occur, and that they can play a role in preventing these errors. The patient is the final link in the medication-use process. As such, an alert and knowledgeable patient can serve as the last line of defense in preventing medication errors. We have many reports in our database of errors that were prevented by observant and informed patients or their families. Thus, to prevent errors, patients must receive ongoing education by physicians, pharmacists and nurses about drug brand and generic names, indications, usual and actual doses, expected and possible adverse effects, drug or food interactions and how to protect themselves from errors. Table IX-1 lists strategies that patients should use.

Table I X-1

Consumer Measures for Error Prevention^{19,20}

Be aware that medicine mix-ups due to look- and sound-alike names are not uncommon

Know what medications you are taking and why

Make sure your doctor tells you the purpose for each medication and writes it on the prescription itself

Know the name and strength of a prescription before leaving prescriber's office

When you pick up a prescription, always speak to the pharmacist to review the medication and directions for taking it

Make sure the pharmacist mentions the same purpose the doctor mentioned to assure that the right drug has been dispensed

Know how to take medications and understand directions

Ask questions, if in doubt, and persist with questioning until you are certain you are receiving the correct drug

Keep a list of medications you take, including dietary supplements and over-the-counter medications

Update the medication list whenever a change occurs



Consumer Measures for Error Prevention^{19,20}

Give an updated copy of your medication list to all healthcare providers at every visit

Learn generic drug names as key identifiers

Tell all practitioners who care for you about changes in your health

Ensure that refilled prescriptions contain the drug you were expecting

Ask for written information about prescribed medications

Contact health professionals if a look- and or sound-alike error is suspected

Patients can play a vital role in preventing medication errors when they have been encouraged to ask questions and seek satisfactory answers about their medications before drugs are dispensed at a pharmacy. If patients question any part of the medication dispensing process, whether it be to question the drug appearance or the correct dose, pharmacists must be receptive and responsive, not defensive. All patient inquiries should be thoroughly investigated before the medication is dispensed.

Error with Patient Education causative factors

Example IX-1: A 17-year-old female track star died following the use of OTC muscle pain relief cream (e.g., Bengay, Icy Hot). The high school teen reportedly used a methyl salicylate cream to treat muscle pain following track meets. In addition to spreading the cream on her legs, she was using other methyl salicylate-containing products as well.

Recommendations

Example IX-1: Use this event as a "wake up" for educating patients about their use of OTC products. Pharmacists should be easily accessible to speak with patients when they select OTC medications. Educate patients about the dangers of methyl salicylate overuse and that it is available in many OTC products. Utilize "shelf talkers" near methyl salicylate and other selected OTC products to raise awareness.

Error with Patient Education causative factors

Example IX-2: A tragic event occurred in which a 6-year-old girl died of an accidental overdose of fenta**NYL**. When the child complained of neck pain late one evening, her foster mother gave her an appropriate dose of ibuprofen but also placed a leftover fenta**NYL** patch on the child's neck to help treat the pain. The next day, the child was found unconscious in bed and was pronounced dead by the time she arrived in the emergency department. The child's foster mother had been given a prescription for fenta**NYL** patches several years earlier to treat chronic pain after an accident. The patch she placed on the child was left over from that prescription.



Recommendations

Example IX-2: This tragedy could have been avoided had the foster mother received adequate education when the fenta**NYL** patches were first prescribed and dispensed. Patient education at time of dispensing should include oral and written instructions on the proper disposal technique (fold and flush), the fact that fenta**NYL** can be fatal if given to another (opiate naive) person and that fenta**NYL** is not indicated for short term pain relief.

IX. Common Contributing Factors Involving Patient Education

Lack of information given to patient

Non-compliance not addressed

Patients not encouraged to ask questions

Lack of pharmacy staff identification (technician vs. pharmacist name tags)

Lack of response to patient inquiries

Lack of encouragement from pharmacy staff for patients to engage with pharmacist

Patient did not properly identify self at pick up

Counseling not encouraged or accepted

No mandatory counseling on high-alert medications

Lack of understanding of written information due to low health literacy or poor reading skills

Patients lack recall of spoken directions

Patient language barrier

No instructions given for devices purchased at pharmacy counter

Patients not given information on medication errors and ways they can help prevent them

No follow up with patients considered to be high-risk or on high-alert (see glossary) medications

Patients eligible for MTM services are not identified



IX. Patient Education Suggested Risk Reduction Strategies

Onsite Staff Implementation

Provide pharmacy applied auxiliary warning labels in a consistent location for patient routine expectation

Use vial size large enough to contain all of the medication and also large enough to have all necessary labels comfortably affixed

Use common sense when applying auto-printed patient warning labels to patient vials

Example from a community pharmacy: A 16-year-old patient brought in a prescription for PLAN B (levonorgestrel), used for emergency contraception. Pharmacy staff applied an auxiliary label that read "*Do not take if you are pregnant or think you may be pregnant*" to the product.

Teach patients how to actively participate in their proper identification before accepting medication at pick up

Provide patients and caregivers with brand and generic names of their medications, the purpose of the medication, dosing, and important adverse effects of their medication, orally and/or in writing

Update patient profiles in the computer system to include all drug products currently being taken whether prescription or not, whether received from this pharmacy or not, and keep these other products in mind when counseling and performing DUR; inform patients of interactions, duplications, and dangers

When dispensing oral liquid medications for children or geriatric patients, a proper measuring device is provided (e.g., dropper) or suggested (e.g., oral syringe) and caregivers are instructed on its use to measure the prescribed dose; consider using only metric quantities and providing metric measuring devices for consistency and accuracy (avoid "teaspoonful" and "cc" terms)

Utilizing a "teach back" method, provide patients with instruction on proper use and maintenance of devices dispensed from the pharmacy; see Figures IX-1, IX-2

Corporate/Owner Action

Encourage staff to solicit patient questions about their prescriptions, OTC, herbal and dietary supplements

Provide pharmacy's telephone number, and the number of an on-call pharmacist or a 24-hour pharmacy if a pharmacist onsite cannot be reached after hours for an emergency

Encourage patients to call for any drug therapy concerns or questions that arise after they leave the pharmacy

Provide adequate staff time for patient counseling activities

Insist on mandatory counseling for patients receiving high-alert medications or for patients considered to be high-risk



IX. Patient Education Suggested Risk Reduction Strategies

Provide a private, confidential area near the pharmacy for patient counseling, MTM services, and educational classes for patients

Provide written information about their medications at a reading level that is comprehendible to patients

Provide pictograms or other means of instruction to patients who do not speak English or are unable to read English

Provide educational classes to patients on medication, disease states or medication safety

Encourage pharmacists with time and resources, to seek out patients who would benefit from MTM services and include MTM services delivery as part of the pharmacist staffing schedule

Encourage pharmacists to participate in promoting, facilitating and providing immunizations to the local community and screening clinics to promote early detection of disease

Encourage personnel to develop and conduct at least one annual educational program or other proactive public health effort designed to improve safe use of medications in the community; see Figures IX-3, IX-4, IX-5



Figure IX-1 OptiClik device as pictured on sanofi aventis website does not warn patients that when held upside down (such as by a left handed person), the dial-up dose could be mistaken due to digital numbers





Figure IX-2 Inform patients that the dose dialed for 52 units appears as only 25 units if held upside down; mistaken doses could result in hypo or hyperglycemia, depending on the digit configuration and the actual amount administered (12 misinterpreted as 21, 51 misinterpreted as 15, etc.)



Figure IX-3 America's Medicine Cabinet *Proceed with (Pharmaceutical) Care*, a program created by APhA and ISMP, emphasizes the importance of reading medicine labels (especially the Drug Facts label) and involving the community pharmacist in medicine decisions. The program introduces consumers to information about and an approach to medicine use that may help them with self-medication choices for themselves and in their role as caregiver. The lesson uses scenarios to teach the importance of reading label warnings and not taking two medicines that contain the same active ingredients. This free program is available at: www.pharmacist.com/Content/NavigationMenu3/Newsroom/PublicRelationsResources/Use_Medicines_Safely.htm.





Figure IX-4 CDC resource page. Centers for Disease Control and Prevention Web site. Available at: <u>www.cdc.gov/flu/freeresources/print.htm</u>.



Figure IX-5 CDC Resource page. Centers for Disease Control and Prevention Web site. Available at: <u>www.cdc.gov/getsmart/campaign-materials/onepage-sheets.html</u>.



Quick Check Question: Patient Education

- 1. The last line of defense in preventing a medication error is the:
 - A. Nurse
 - B. Prescriber
 - C. Patient
 - D. Pharmacist

Answer: C. Patients are the last line of defense in preventing a medication error. They are an integral part of their medication safety team and should be treated as valued team members.

- 2. Which of the following are ways to prevent medication errors through patient education?
 - I. Provide education for all medications dispensed
 - II. Provide education for all high-alert medications
 - III. Encourage patients to review prescriptions before leaving the pharmacy
 - A. I only
 - B. III only
 - C. I and II
 - D. II and III
 - E. I, II, and III

Answer: E. Patients are routinely asked if they have any questions for the pharmacist and they often say no. However, this question places the responsibility on the patient to know that he or she should ask questions or what questions need to be asked. Pharmacists should be proactive and provide patient counseling, especially for high-alert medications or ones that use a device. This prepares the patient to appropriately and safely use the product. It also provides an environment in which a patient can ask questions and a pharmacist can identify potential problems before the patient leaves the pharmacy.



Key Element X: Quality Processes and Risk Management

A non-punitive, systems-based approach to error reduction is in place and supported by pharmacy owners or senior management.

Practitioners are motivated to detect and report errors, and teams or individualized practitioners in small pharmacies regularly analyze errors that have occurred within the organization and in other organizations for the purpose of redesigning systems to best support safe practitioner performance.

Simple redundancies that support a system of independent double-checks or an automated verification process are used for vulnerable parts of the dispensing system, to detect and correct serious errors before they reach patients.

Background

Traditional efforts at error reduction have focused on individual practitioners, using training, exhortation, rules and disciplinary action to improve performance. Human factors specialists and error experts reject this approach because it is more effective to change the system as a whole than to target individuals for improvement.²¹ Since most of what people do is governed by the system, the causes of error belong to failures in the system and often lie outside the direct control of the individual workforce. Therefore, the way to prevent errors is to redesign the systems and processes that lead to errors rather than focus efforts on correcting the individuals who make errors. Effective strategies for reducing errors include making it impossible or difficult for staff to make an error, and promoting the detection and correction of errors before they reach a patient and cause harm.

Although reducing complexity in processes is important to error reduction, simple redundancies that support a system of independent double-checks promote the detection and correction of errors before they reach patients. These checks are most effective when used for drugs which have the potential to cause serious patient injury.

Learning about errors and near misses that have occurred in other organizations, and reviewing safeguards others may have implemented, can help prevent similar errors from occurring in other practice settings. Each organization needs to accurately assess how susceptible its systems are to the same errors that have happened in other organizations, and acknowledge that the absence of similar errors is not evidence of safety. Personal experience is a powerful teacher, but the price is too high to learn all we need to know from firsthand experiences. Learning from the mistakes of others is imperative. Pharmacy teams should review items from the most recent *ISMP Ambulatory Care Action Agenda* (see Figure X-1) in order to stimulate discussion on what type of actions may reduce the risk of medication errors.



isue No.	Problem	Recommendation	Organization Assessment	Action Required/Assignment	Date Complete
		EXUBERA (insulin human [rD	NA origin]): risk of dosing er	rors	
1	Evaluent is a new individed intern al insulin dised in rug. Catariana between disease: new individed in rug and units sensi insettable. The exploalency of mg to units is not evenly incormontal (1 rug is equal to 3 units), to 45 ang is equal to 8 units, and 8 units), ads, careacutive indiation of threa. Trug bitters reads in greater insulin exposure than inholation of one 3 rug bitster.	To essaye progen use, young produktioners about the petertal for average when docking Exoloren. Also extende patients about patiential datas centrication before presentition, dispersing, and/or administering the product.			
		DIASTAT ACUDIAL (diazer	pam rectal gel) dosing errors	1	
3	Finite how ensured when Datati Auxilia, a prefilled diazpan netal synthey, use net dialet, est, and locked to the present bed diase by the diasensing planmacki. This has bappened even if the monitorum datas callidate in the synthey. (Um our 22 Jung) was presentied. Some of the dataing errors have led to respirative depression requiring emergent interventions.	Parametrists should elsek that the hole loss been dailed and ledeal for bath systems: In each package. Practitioners should elabele patients and compress about process and the elseks, including confirming that the presented dase is visible in the display voltancy, the green modely hand is visible, and the appropriate redsh tip size is used for the age and size of the patient.			
		OptiClick pen: p	roblematic design		
11	LANTUS disculing alongine (IDDA origin) togentum) and APIDRA (Instalin dialism (IDDA origin) injectiony are available in 63 mL cartitidges to be used with the OptiClack peri device. The period the dealed in the varing dass if it is oriented in the varing direction; it would be held "usebareatic" with mercell to the right, ensuing the marrhers to be upside drawn.	Demonstude to the patient how to insert a new cartridge, attack an needle, and messore and administer a does. Histatel to patients the proper way to hold the device to ensure the number in the dase devices window is sitewal correctly. Here the patient demonstrate runnous use of the device before learning your practice site.			

Figure X-1 The ISMP Ambulatory Care Action Agenda. The Action Agenda is presented in a format that allows community practice sites to document their medication safety activities, which is important for internal quality improvement efforts as well as for any external accrediting or regulatory organizations. Each pharmacy practice site should convene a staff meeting to discuss each item in the Action Agenda. The staff should ask themselves, "Can this error occur at our site?" If the answer is "yes," the ISMP recommendations for prevention should be reviewed for applicability at that specific site. If the recommendations are germane to the practice site, the columns on the Action Agenda indicating "Organization Assessment" and "Action required/Assignment" should be completed and a reasonable time set for completion.

It is important to explore how to use reported medication error information to identify potential areas of opportunity within pharmacies and/or the organization. Organizations must support a culture of safety and establish a non-punitive approach to internal reporting of errors in order to detect, document, assess and prevent prescription errors and to determine the causes and appropriate responses.

Voluntary adverse event reports often lead to corrective actions such as widespread dissemination of hazard alerts by ISMP, FDA, and manufacturers (see Figure X-2); product label revisions, and even changes in drug names. For example, after several deaths were reported following mix-ups between amrinone and amiodarone, ISMP petitioned United States Adopted Names (USAN) to change the proper name, amrinone, to inamrinone. This has effectively eliminated this problem name-pair, along with associated deaths. LEVOXINE, a thyroid product, was



occasionally confused with LANOXIN, a digitalis product, until the maker of LEVOXINE agreed, in 1994, to change the name to LEVOXYL.

and the second se	
Have similar names and dosage strengths Are often stocked in close proximity on pharmacy shelves	
Help minimize medication errors.	au-
When communicating with patients and health care professionals say "TOPROL-XL" clearly	
Take the time to legibly print all prescriptions	
Include brand name, generic name, and indications on all prescriptions ¹	(netoprolof succinate)
Encourage patients to know their medications by name and appearance	50 mg once daily for hypertension
☑ To help us better understand the reasons for and way to avoid medication errors, you can contact the AstraZeneca Information Center at 1e00-236-9933, the FDA at 1-800-FDA-1088, or the US Pharmacopeia at 1-800-23-ERROR	24 Normania (Stranger Stranger
TOPROL-XL is indicated for the treatment of hypertension, alone or in combin	nation with other antihypertensive agents.
TOPROL-XL is contraindicated in severe bradycardia, heart block greater than fil cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place component of this conduct.	ist degree, cardiogenic shock, decompensated), and in patients who are hypersensitive to any
Patients taking TOPROL-XL should avoid abrupt cessation of therapy. Fi certain 8-blocking agents, exacerbations of angina pectoris and, in som the design should be reduced gradually over a 1- to 2-week period, an	blowing abrupt cessation of therapy with te cases, myocardial infarction have occurre d the patient should be carefully monitored.
the second strength and the se	tic disease, diabetes, thyrotoxicosis, e calcium channel blockers of the verapamil
TOPROL-XL should be used with caution in patients who have bronchospas peripheral vascular disease, who are undergoing major surgery, or who take and difficatem type.	
TOPROL-XL should be used with caution in patients who have bronchospan peripheral vascular disease, who are undergoing major surgery, or who tak and dilitacent type. Inform patients to avoid activities that require alertness utili their response to 1	herapy with TOPROL-XL has been determined.
TOPROL-3L should be used with caution in patients who have brenchrospan peripheral vancular disease, who are underplain quark surgery, or who has and distance they and disease events reported with limited are response to inform patients to racid activities that require identees until their response to the most common advense events reported with limiteddar-takes materoal angina are firedness (10%), dzimes (10%), depression (9%), damhea (9%), and brahycanda (3%).	herapy with TOPROL-XL has been determined. of tartrate in patients with hypertension and pruritus or rash (5%), shortness of breath (3%).
109980 A should be seted with cardien in patients who have hardchoose operational vacuum of the sete of the set of the set of the set of the and diffusion types. The set of the set of the set of the set of the first patient by the set of the The nod common advance events reported with immediate insteam tempora- tion and the set of the and transport (M), discrimes (DN), discrimes (DN), diartime (DN), and transport (DN), discrimes (DN), discrimes (DN), diartine (DN), pass set object the fill set of the set of the set of the performance, including to the set of the set of the fill set of the set of the performance, including the	herapy with TOPROL-XL has been determined. of tartrate in patients with hypertension and pruritus or rash (3%), shortness of breath (3%), ad WARNING regarding abrupt cessation of therap
109983. A should be used in cade in justimet when the theorem to perform a subscription of the same should be a subscription of the same type. In the and different type. In the same should be the same should be the most common advected events reported with immediate-release material and an advected be the same should be and an advected be the same should be and an advected be same should be advected by the same should be advected by the same should be advected by advected	herspy with TOPROL-XL has been determined, of tartrate in patients with hypertension and pruritus or rash (5%), shortness of breath (3%), and WARNING regarding abrupt cessation of thorap 527-30 L der Commans of Accelutors (Hertnes
100903. A double be used with calders in patients who have trackingen- performed security datasets, who are univergating major surgery, or with bia and difficure types. The social darkWeb bit regards addresses until their regioners to the most common adverse events reported with immediate whether their adjust as at traitients (1%), durings (1%), durings (1%). Approx. Phase are adjusted bit for dark the social dark their social dataset bits of the social dark their social data and the social dataset bits (1%). Phase are adjusted bits for dark the social bits and the social dataset bits for adjusted to the social data and the social dataset bits (1%). Phase are adjusted bits (1%) and the social dataset bits (1%) and the social for adjusted to the social dataset bits (1%) and (1%).	herspy with TOPROL-XL has been determined. Is laritable in galaxies with hypothersion and pruntus or math (SN), shortness of breath (SN), and WARNING regarding alongs cessation of thersp (SI7 9 L. J. et Germans et Accentitute of Institute
100903 A sould be used with calation in patients who have trackings opphend waxaed states, who are univergenting maps arguings, or who has and diffarm type. Inform patients to accide landwise that require winth two markets and para as therefore the following and the immediate states metages and the source of the landwise with immediate states metages and a set to accide an object of the following opphendix of the following and the source of the distances of the following opphendix patients are associated as a source of the following the there is an an object for the distance of the following opphendix of the following the the following a set to access on the following the the following the the following as a source of the following the following the the following following as a source of the following the following the the following following as a source of the following the following the the following following as a source of the following the following the the following as a source of the following the following the the following as a source of the following the following the the following as a source of the following the following the following the following as a source of the following the following the following the following as a source of the following the following the following the following as a source of the following the following the following the following as a source of the following the following the following the following as a source of the following the following the following the following as a source of the following the following the following the following as a source of the following the following the following the following the following the following the following the following the following the following the following the following the following the following the following the	hestopy with TOPPIOL-NL has been determined. In landau in cationites with hypertension and pruntum or rank (NN), shorthesso of breach (NN), and NAPANNO regarding should consistent of thorage of NT N L and Genemic in Annualisation of thorage CONTON I L and Genemic in Annualisation of thorage

Figure X-2 AstraZeneca's one page magazine campaign toward awareness of look-alike drug names, after error reports involving their product were brought to their attention

Internal error reporting can help identify error-prone conditions in an organization's medication-use system. Once system deficits are identified, proactive measures such as auxiliary labeling, drug storage changes, or pharmacist/staff education may be undertaken to remedy these conditions and prevent similar future mishaps.

Reports to voluntary reporting programs, such as the ISMP MERP, from frontline pharmacy staff are especially important when errors involve LASA products because high-level, error-reduction strategies, such as drug name changes or packaging alterations (see Figure X-3), are sometimes needed to prevent future errors. Product problems may occur with a frequency that should constitute a "call to action," but the incidence or significance of those problems may be lost within the construct of individual practice settings.





Figure X-3 Apidra/Lantus labeling and packaging before error reports (left) and after error reports (right); accumulated medication error reports both by pharmacy staff and patients, indicating look-alike packaging contributed to selection errors, convinced manufacturer to change label and box appearance

Voluntary reporting programs have learned that many errors are caused by factors outside the healthcare practice site and beyond the direct control of a pharmacist. Thus, safe practice recommendations have been communicated to medical device manufacturers, pharmaceutical companies, automation technology companies, healthcare reimbursement systems, and others less directly involved in patient care, but nonetheless influential in the safe provision of care. Take the time to report errors and potential errors to ISMP. Without reporting, such events may go unrecognized and thus important epidemiological and preventive information would be unavailable. Errors, close calls, or hazardous conditions may be reported through the ISMP web site (www.ismp.org) or communicated directly to ISMP by calling 1-800-FAIL SAFE or via e-mail at merp@ismp.org. ISMP guarantees the confidentiality and security of the information received.

Error with Quality Processes and Risk Management causative factors

A patient reported being very dissatisfied with the way his community pharmacist responded when a dispensing error resulted in nearly 30 days of erroneous therapy. Unfortunately, this pharmacist's sense of infallibility contributed to the original error, and the perception that she was uncaring impeded an appropriate apology and service recovery actions when the error was discovered.

Recommendations

Investigate patient concerns when prescriptions are picked up; use patient counseling sessions as a final check of prescription accuracy. Schools of pharmacy and employers should provide education to pharmacists to ensure they possess requisite knowledge and skills to respond when errors occur. Conveying sympathy, preserving relationships, and fostering trust should be seen as appropriate



professional actions in the aftermath of an error. Report and discuss errors with all staff. Lead group discussions on prevention strategies and implement workable solutions.

Х.	Common Contributing	Factors	Involving	Quality Processes	and
Ri	sk Management				

No clear culture of safety (see glossary)

Lack of leadership and budgetary support for medication safety

Incentives and positive feedback not given to individuals who report errors and hazardous situations

Fear of error reporting (blame, humiliation, retribution; tied directly to performance reviews, continuation of employment and monetary compensation)

Error prevention strategies focus on individual performance improvement rather than systems improvement

Error rates are used for benchmarking and kept in employee files

Independent double-checks on calculations for pediatrics or compounds not performed

Lack of automated or manual double-checks in critical processing steps

System-based causes of errors not analyzed

System-based enhancements not sought or implemented

Misuse of double-checks, in place of system enhancements that would prevent errors

Over reliance on scan accuracy of system technology (when overrides of the system are allowed)

X. *Quality Processes and Risk Management* Suggested Risk Reduction Strategies

Onsite Staff Implementation

When possible, (i.e., during pharmacist staffing overlap or via contact with off-site colleagues*), ask fellow pharmacists to double-check all calculations

During staff meetings, promote and reward reporting of errors and their prevention

Do not permit assigning of blame to prescription incidents

On a daily basis, a pharmacist compares the previous day's prescription orders listed on a computer-generated printout with hard or scanned copies of the prescriptions, to verify data entry accuracy



X. *Quality Processes and Risk Management* Suggested Risk Reduction Strategies

Pharmacists periodically perform quality control checks by reviewing completed prescriptions in the will-call area; examining typed labels, computer entries, and location of stock bottles replaced in inventory; and other forms of random checks that promote detection of errors

Corporate/Owner Action

Promote patient safety and quality of work as manager's (corporation's) objectives and mission

Promote a culture of safety from top management down to staff in pharmacies

Practice and promote just culture and shared accountability when discussing errors

Identify and coach at-risk behaviors

Management provides positive incentives for individuals to report errors, and pharmacists and technicians are thanked and praised for detecting and reporting errors

Pharmacists and technicians are periodically and anonymously surveyed to determine their level of anxiety and fear with making and reporting errors

Pharmacists and technicians involved in serious errors that cause patient harm are emotionally supported by their colleagues, and offered psychological counseling through an Employee Assistance Plan

Encourage management to be skilled in "human factors" to recognize when staff needs "filters" added for safety

Encourage staff to notify management when unsafe environmental conditions exist

Reward staff when reporting near misses and errors for educational and training purposes

Train pharmacists and technicians in the clinical and administrative procedures for responding to a serious medication error

Use discipline in cases of malicious or illegal activity, using the Just Culture process and algorithms

Encourage regular visits of upper management to the pharmacy, to seek staff input on ways to help prevent medication errors, improve processes and decrease hazardous situations

Do not allow fear of retribution in the reporting of errors and near misses

If the pharmacy discovers that an error has led to improper medication dispensing, regardless of the level of harm that results, disclose the error to the patient/caregiver/family in a timely manner

Convene a medication event team to routinely review and analyze errors, to identify system-based causes and facilitate implementation of system-based enhancements



X. *Quality Processes and Risk Management* Suggested Risk Reduction Strategies

Continually disseminate information throughout the organization about systembased errors and high-leverage safety strategies

Develop a system of independent double-checks even if only one pharmacist is staffing each shift

Seek and disseminate external error reports which identify errors and safety strategies that could affect the organization

*Off-site colleagues could include remote fill sites, remote data entry sites, etc. The pharmacist doing data entry does a final check prior to the transmission of data to the remote filling site. At the remote site, a second review by a pharmacist takes place. On remote data entry the same occurs. The prescription is scanned, all patient data is available to the remote data entry site, and the pharmacist at the filling site reviews the remote data entry information for completeness and accuracy once the remote data entry information is transmitted back to the filling site.

Quick Check Question: Quality Processes and Risk Management

- 1. Which of the following could occur as a result of voluntary internal or external medication error reporting?
 - A. The FDA could mandate the manufacturer change the medication name to avoid nomenclature confusion.
 - B. Hazard alerts could be disseminated by FDA, ISMP and manufacturers.
 - C. Internal, site-specific actions such as auxiliary labeling, drug storage changes, or pharmacist/staff education may be undertaken to remedy reported errors, to prevent similar future mishaps.
 - D. All of the above

Answer: D. As you can see, there are many benefits to voluntary error reporting. Without reporting medication errors, near misses, and hazardous conditions; there is no way to identify and fix faulty systems. Work to develop a Just Culture. Engage staff in uncovering and repairing system design flaws before human errors occur. These steps will encourage open communication, making it easier to create and implement error-reduction strategies.



Final Quick Check Question

- 1. A prescription for Zy**PREXA** (olanzapine) is telephoned to a community pharmacy. Zy**PREXA** has been reportedly mixed up with both Zantac (ranitidine) and Zyr**TEC** (cetirizine). Which of the following will help limit errors in this situation?
 - I. The dispensing pharmacist reads back the drug name, dose, label instructions and purpose of the medication to the prescriber, who verifies that all elements have been heard correctly.
 - II. The doctor's office calls the patient to inform them that their prescription has been called in and will be ready for them.
 - III. The pharmacist counsels the patient and makes sure the patient knows why he/she is taking this medication.
 - A. I and II
 - B. I and III
 - C. II and III
 - D. I, II and III

The answer is B. Option II is incorrect because even though the doctor provided great customer service by calling the patient to let them know their prescription was ready, the patient did not know the name or type of medication that was called in to the pharmacy.



Using the Assess-ERR[™] Tool in Community Pharmacy

The **ISMP** *Assess-ERR*[™] found in Appendix 3 is a simple three step medication system worksheet designed to assist pharmacists and pharmacy operators with error report investigations. Use the *Assess-ERR*[™] tool to record errors, near-errors, and/or hazardous conditions. Examples of errors to address with the *Assess-ERR*[™] tool include dispensing the wrong drug, strength, or dose; look-alike/sound-alike errors; calculation or preparation errors; misuse of devices; and errors in prescribing, transcribing, dispensing, and/or monitoring of medications.

Using the Assess-ERR[™] helps a pharmacy convert a negative error experience into a positive learning experience that enhances the overall future safety of that pharmacy's practice. The tool aids in developing a standardized approach to documenting error incidents and helps to reveal the underlying system deficiencies that may have caused or contributed to the error. Additionally, the tool can help raise awareness of issues that have become so familiar to pharmacists in a particular practice setting that the issues are no longer even recognized as risks.

The suggested actions mentioned in each Key Element can be used to help identify the risk-reduction strategies called for in the *Assess-ERR*[™] tool. Space is provided on the *Assess-ERR*[™] form to document proposed interventions, staff responsibilities, the implementation process, and any immediate required actions (changes to policies, procedures, systems or processes).

Once the problems are identified using the *Assess-ERR*[™] tool, use the strategies below to establish appropriate action.

- Fail-safes and constraints involve true system changes in the design of products or how individuals interact within the system. For instance, when the pharmacy computer system is integrated with the cash register, a fail-safe would prevent the clerk from "ringing up" the prescription unless final verification by a pharmacist had occurred.
- Forcing functions are procedures that create a "hard stop" during a process to help ensure that important information is provided before proceeding. For example, a pharmacy computer system that prevents overriding selected high-alert messages without a notation (e.g., patient-specific indication must be entered if high-alert medication selected)
- Automation and computerization of medication-use processes can reduce reliance on memory. Examples include true electronic systems that can receive electronic prescriptions from a prescriber, thus eliminating data entry misinterpretation at the pharmacy; and robotic dispensing devices.



- **Standardization** creates a uniform model to adhere to when performing various functions and to reduce the complexity and variation of a specific process. For example, create standardized processes to guide the pharmacist's final verification of a medication or to enhance the safety of giving or receiving a telephoned medication order.
- **Redundancies** incorporate duplicate steps or add another individual to a process, to force additional checks in the system. Involving two individuals in a process reduces the likelihood that both will make the same error with the same medication for the same patient. However, the potential for error still exists since the redundant step may be omitted or ignored. Examples include use of both brand and generic names when communicating medication information. Patient counseling is often an underutilized redundancy that can detect many errors.
- **Reminders and checklists** help make important information readily available. For example, prescription blanks that include prompts for important information (e.g., medication indication, allergies, patient birth date).
- **Rules and policies** are useful and necessary in organizations. Effective rules and policies should guide staff toward an intended positive outcome. However, some may add unnecessary complexity and may be met with resistance, especially when implemented in haste in response to an error. Because their use relies on memory, they should be used as a foundation to support other strategies that target system issues.
- Education and information are important tactics when combined with other strategies that strengthen the medication-use system. The effectiveness of these tactics relies on an individual's ability to remember what has been presented. Thus, on their own, they offer little leverage to prevent errors. An example of an education strategy would be having pharmacy personnel read and review policies and procedures on how to correctly perform a function such as prescription verification.

Use a variety of the above strategies to focus on system issues and human factors, to continually enhance safety procedures in your pharmacy. Share this information with colleagues at your site and within your greater organization.


Illustrating the Application of the Key Elements through the Medication Flow Process

Medication flow process, case scenarios and key element causative factors

Two ways to employ risk assessment are to develop a flow diagram and present a case scenario utilizing the actual or potential adverse drug event information. This section presents an example of a flow diagram, and the next section presents two case scenarios with completed sample *Assess-ERR*TM tool documents, to illustrate how the risk assessment thought process can be used to further help a pharmacy in medication error prevention.

Process Flow Diagrams

An easy method to help identify the steps in a pharmacy's medication-use system is to develop a process flow diagram of the system. The diagram should be created with the help of all the individuals involved in the medication-use process (pharmacists, pharmacy support staff, interns, etc.). The diagram can be very detailed or may include just the basic steps in the process.

Questions for Exploring the Process

The questions used in the following section are to be used during the analysis of a medication incident and are not meant to be all-inclusive; they should help the assessment team begin thinking of safety characteristics that should be incorporated in their process. The questions within each process may be directed to each staff person most actively involved in the process being described.



A. Triage and Order Entry



- Is a complete medication history taken on all new patients that includes prescriptions, OTC medications, vitamins, herbals and dietary supplements?
- Are allergies verified and documented in the computerized patient profile?
- Does pharmacy staff inquire from patient, prescriber or prescriber's agent the indication for use or diagnosis?
- Is staff aware of and instructed never to use dangerous abbreviations and dosage designations?
- Is patient date-of-birth on each hard copy prescription and correctly inputted in pharmacy system, and highlighted if patient under 6 years of age?
- Is female patient's pregnancy status known if applicable (prescribed a category X drug)?
- Does technician/pharmacist repeat back and spell out all spoken medication orders?
- Are prescribers immediately contacted to verify missing, illegible or ambiguous prescriptions?



B. Pharmacist Verification I – Verifying pharmacist



- Are all reference texts current and up-to-date?
- Is there online reference available?
- Is the patient profile readily accessible (number of keystrokes is limited to access profile in system) when verifying new prescription?
- Is the original prescription readily accessible (scanned image or hard copy) for confirmation of data entry?
- Does the computer automatically screen for allergies, drug interactions, maximum doses, etc.?
- Is pharmacist able to distinguish and resolve, via the computer system or manually, issues with interactions, allergies, duplicate therapy and other drug utilization alerts?
- Does the computer system contain warnings and alerts for look- and sound-alike drug products?
- Does the computer system warn when high-alert medications are being dispensed?
- Are independent double-checks performed on all high-alert medications?



C. Product Pick – Technician



- Does the pharmacy buy product with potentially confusing names and packages?
- Is staff properly trained to initiate extemporaneous compounding?
- Are stock bottles with approaching expiration dates easily recognized?
- Is the workspace and lighting adequate for medication storage and preparation?
- Are medications with look- and sound-alike names and packaging stored separately?
- Are refrigerator and compounding stock stored safely in well-lighted, appropriately labeled shelves?
- Are automated dispensing and counting devices kept on manufacturers' suggested maintenance schedules for cleaning and calibrating?
- Are shelf dividers used in crowded areas?



D. Pharmacist Verification II – Verifying pharmacist



- Are medications checked against the label and the original order before they are dispensed?
- When issues or discrepancies are noted, is the product sent back to the stock selection stage and the problem used as a teaching/training opportunity for the entire staff?
- Is there an independent double-check performed when high-alert or lookand sound-alike medications are being verified?
- Is product verification bar coding available?
- Is there a method to ensure that correctly-typed labels are applied to the correct person's prescription vial (labels not inadvertently switched for same patient or different patient)?
- Are prescription orders separated by person and worked on one at a time (basket system)?
- If the manufacturer does not provide a barcode or NDC number on the unit-of-use package, is there a fall back procedure to ensure correct product is being dispensed?
- Are ergonomic factors considered in the verification work space: lighting, temperature, work space sufficient and free of clutter, magnifiers, computer terminals, trash receptacles, fatigue mats, etc.?



E. Transfer to Will-Call Area



- Is the will-call/pick-up area neatly organized and spacious enough so bagged prescriptions are not misplaced?
- Is there a system to ensure split orders for the same patient are put together at pick-up so patient does not leave with only part of their order (waiting for prescriber call back, out of stock, etc.)?
- Are patient-specific labeled prescriptions needing reconstitution, refrigeration or pharmacist intervention/counseling flagged as such and stored separately?
- Is there a return to stock policy to ensure timely pick-up of completed medication orders?
- Are the bins, drawers, baskets, etc. large enough to accommodate the filled prescriptions waiting to be picked up?
- Is this pick-up area a candidate for see-through hanging bag system of retrieval?
- Are completed prescriptions segregated so that "filled today" are separated and easily retrieved?
- Is the pick-up area confidential? Can patient receipts be seen by others at the counter?
- Is the pick-up area well lit?



F. Point of Sale



- Has staff been trained to ask for two forms of patient identifiers?
- Have patients been trained to give two forms of patient identifiers and educated as to why it is important for them to verify the filled prescriptions are theirs before leaving the pharmacy?
- Has staff been trained to deliver oral measuring devices when dispensing oral liquid medications?
- Are refrigerated or reconstituted items retrieved and given to the pharmacist to verify/reconstitute?
- Does staff open contents of bag and cross-check for omitted items, extra items and that labeled vial(s) match attached receipt(s)?
- Is the offer to counsel made in a positive manner to encourage an affirmative response?
- Is the complete consumer medication information (all pages) dispensed with the filled prescriptions?
- Are medication guides dispensed as required by law?
- Are pharmacists called upon to counsel on all prescriptions indicating "mandatory" counseling or when the patient requests counseling?
- Are patients informed about look- and sound-alike medications that could be confused with their current medication?
- Are patients encouraged to ask questions and to notify the pharmacist if they experience any problems with their medication?
- Are patients directed to a private consultation area when the prescription receipt indicates mandatory counseling by the pharmacist or when a patient accepts the offer of counseling?
- Are there certain medications that trigger a consult with a pharmacist for patient education?
- Are technicians aware of the high-alert medications or if a medication has a heightened error potential so that they can take extra precautions when dispensing?



Utilizing the Assess-ERR[™] (Case Study)

Introduction

The "case study" is a mechanism to teach pharmacy staff about risk assessment and identifying failures in the medication dispensing system. The case could involve an actual medication error or near miss that occurred internally, one obtained from the literature (such as reports in the *ISMP Medication Safety Alert!*[®] and The Joint Commission Sentinel Event Alerts), or an error or near miss that could happen (for example, one discussed while performing an FMEA).

The case examples below will illustrate where system breakdowns occurred in relation to the *Key Elements of the Medication Use System*TM. An error description is provided for each case. To illustrate analysis of the error example, system risks and failures are identified for each step in the dispensing process.

In order to identify potential systems-based risk-reduction strategies, use the appropriate Key Element recommendation charts provided in previous sections.

ISI	MP's Key Elements of the Medication Use System [™]
I	Patient information
11	Drug information
111	Communication of drug orders and other drug information
IV	Drug labeling, packaging, and nomenclature
V	Drug standardization, storage, and distribution
VI	Medication device acquisition, use, and monitoring
VII	Environmental factors, workflow and staffing patterns
VIII	Staff competency and education
IX	Patient education
Х	Quality processes and risk management

These case study examples are not meant to be Root Cause Analyses or all inclusive of possible risks or causes that could have contributed to the error. They are intended to serve as a review of the medication flow process and to stimulate thought and discussion on the risks involved in actual cases. Hopefully it will be used as a risk assessment tool to identify failure points in the medication-use system before they can lead to serious harm.



The following case study examples have been entered into the $Assess-ERR^{\text{IM}}$ tool found in Appendix 3.

Case Study Example One: Description

The Error

A patient living in a group home was acting "differently" and was clearly more agitated. The prescriber ordered a test of Lithium levels done on the patient. As a result of the low level, the prescriber called the pharmacy to insure that medication had been dispensed correctly. It was then discovered that the wrong medication had been given. Lithium Citrate 8 mEq/5 mL was filled with Chloral Hydrate (Noctec) 500 mg/5 mL, in error.

Review of the Error

Consider where in the process the error occurred, consider contributing factors based on the previous modules, identify the key element (use Key Element table above to reference element numbers when assigning causative factor to $Assess-ERR^{TM}$ tool)

Process Step: Triage and Order Entry				
Contributing Factor	Key Element			
Past medical information, which would have listed the previous therapy of "Lithium" was not readily available	Ι			
Drug name was entered by a technician using the NDC number from a stock bottle and not the drug name indicated on the actual prescription hard copy	II, III, IV			
Purpose or indication for medication was not written on hard copy prescription	I, III			

Process Step: Pharmacist Verification I				
Contributing Factor	Key Element			
Prescription was not verified by comparing the input script information to the original prescribed order	II			
Prescription was not reviewed for therapeutic appropriateness based on health conditions noted in patient profile	Ι			



Process Step: Pharmacist Verification I				
Contributing Factor	Key Element			
Both medications dosed as "teaspoonfuls" at bedtime	II			
The patient's computer profile was not reviewed because it was not easily accessible (took a number of keystrokes to access)	Ι			

Process Step: Product Pick (Selection)					
Contributing Factor	Key Element				
Medication selected by NDC number on label and not verified to hard copy prescription	V				
<i>Lighting in the "liquid section" was inadequate and stock bottles were crowded; there were no shelf dividers between products</i>	V				
The drugs are stored alphabetically. The two drugs were in close proximity on the shelf (Lithium and Noctec), and had similar labels; both manufactured by MGP, and similar look and packaging: both pint-size, plastic, amber-colored bottles with same-colored labeling	V				

Process Step: Pharmacist Verification II					
Contributing Factor	Key Element				
Medication was not checked against the label and the original order	$\mathcal{V}III$				
Ergonomic factors: inadequate lighting, cluttered verification workspace, magnifiers not available	VII				

Process Step: Transfer to Will-Call Area				
Contributing Factor	Key Element			
Patient lived in group home; drug name not visible on receipt	Ι			
No additional final checks done prior to bagging and delivering filled prescriptions	Х			
<i>Previous errors involving group home patients were not communicated to entire pharmacy staff</i>	Х			



Process Step: Point of Sale					
Contributing Factor	Key Element				
Medication delivered to group home; no interaction/counseling between pharmacist and patient, or pharmacist and group home worker; no offer to counsel given	VIII, IX				
Patient in group home not given written consumer medication information (CMI); group home healthcare worker did not read CMI	IX				
Medication administrators in group home are not licensed and have no minimum level of education required to administer drugs, do not check patients' medication charts for accuracy, do not know common indications for drugs, do not check treatment	VIII				



Assess-ERR[™] tool completed for Example One:

Assess-ERR™ Community Pharmacy version

Medication System Worksheet Example One

Rx # <u>1234</u>						
Date of		Date information		Pati	ient	
error:	5-09-09	obtained:	5-10-09	age	:	42
Drug(s) invol ⁱ error:	ved in	Lithium Citrate 8 mEq/	5 mL, Chloral Hydr	ate 500	mg/5 m	L
STEP 1						
Was indicatio prescription?	n for use o	n the		□ Yes	🗵 No	
electronically?						
Were two unique patient identifiers used at pickup? Did the patient accept the offer to						
counsel?						
Did the error	reach the j	patient?		⊠Yes	🗆 No	
Was the preso of the inciden	criber notif it?	ied		⊠Yes	□ No	
Brief description of the event (what, when, and why): Patient living in group home received						
the wrong medication. Lithium Citrate 8 mEq/5 mL was filled with Chloral Hydrate						
500 mg/5 mL (generic for Noctec), in error.						



STEP 2

Key Element	Possible Causes	Y/N	Comments		
I	Critical patient information missing? (age, weight, allergies, pregnancy, patient identity, address, indication for use, etc.)	Y	No indication for use on hard copy prescription and no health condition information in pharmacy computer system; patient lived in group home; drug name not visible on receipt		
11	Critical drug information missing? (outdated/absent references, inadequate computer alerts, independent checks for high-alert drugs/high-risk patient, etc.)	Y	Elderly patient should have been considered high-alert; past patient profile not reviewed for therapeutic appropriateness prior to dispensing (too difficult to access); both medications can be dosed as "teaspoonfuls at bedtime"		
111	Miscommunication of drug order? (illegible, ambiguous, incomplete, misheard, or misunderstood spoken rx, poor fax, unable to clarify with prescriber, etc.)	Ν			
IV	Drug name, label, packaging problem? (look-/sound-alike names, look-alike packaging, no drug image ,NDC or barcode not available or not used, etc.)	Y	Similar labels; both manufactured by MGP; similar look and packaging: both pint-size, plastic, amber-colored bottles with same-colored labeling		
v	Drug storage or delivery problem? (drug stocked incorrectly, stock on crowded shelves, look-alike products stored next to each other, etc.)	Υ	The drugs are stored alphabetically. The two drugs were in close proximity on the shelf (Lithium and Noctec); lighting in the "liquid section" was inadequate and stock bottles were crowded; there were no shelf dividers between products		
VI	Drug delivery device problem? (automated dispensing devices not calibrated or maintained, oral measuring device not dispensed, etc.)	N			
VII	Environmental, staffing, or workflow problems? (poor lighting, excessive noise, clutter, interruptions, human factors, workload, inefficient workflow, breaks not scheduled, etc.)	Y	Inadequate lighting, cluttered verification workspace, magnifiers not available		



Key Element	Possible Causes	Y/N	Comments
VIII	Lack of staff education? (competency validation, new or unfamiliar drugs/devices, orientation process, feedback about errors/prevention, etc.)	Y	Staff entered NDC from stock bottle, not drug name on prescription. Medication administrators in group home are not licensed and have no minimum level of education required to administer drugs; they do not check patients' medication charts for accuracy; they do not know common indications for drugs; they do not check treatment
IX	Patient education problem? (lack of information, non- adherence, not encouraged to ask questions, lack of investigating patient inquiries, patient barriers, etc.)	Y	Medication delivered to group home; no interaction/counseling between pharmacist and patient, or pharmacist and group home worker; no offer to counsel given. Patient in group home not given written consumer medication information (CMI); group home healthcare worker did not read CMI
x	Quality processes and risk management? (No culture of safety, fear of error reporting, system- based causes not analyzed, independent double-check not performed, etc.)	Y	Previous errors involving group home patients were not communicated to entire staff; no additional final checks done prior to bagging and delivering filled prescriptions

Patient Outcome:

Patient treated for low lithium levels



Assess-ERR™ Community Pharmacy version

Medication System Worksheet

STEP 3

As a team, identify, prioritize and record "Identified Problem" from the "Comment" section in Step 2. Using the specific key element for those comments, refer to the recommendation strategies chart and select the most appropriate and effective interventions. Write selected strategies in the "Interventions Implemented" column below. This table will be used to document medication safety activities. Recommended interventions should address breakdowns in the *Key Elements* identified during event investigation. The staff should reconvene in three months time to determine if the proposed strategies have been implemented, if they are still pertinent, and if other strategies have been offered or considered since the initial review. Use a variety of strategies, as found in Appendix 4, to help generate appropriate interventions.

Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed
Past patient profile not reviewed for therapeutic appropriateness prior to dispensing (too difficult to access)	Ι	Obtain clinical purpose of each prescription before the medication is dispensed, to assure that the prescribed therapy is appropriate for the patient's condition and to help distinguish medications with similar packaging and look- alike or sound-alike names. (redundancy) Ensure that the drug ordered matches the clinical indication provided. (redundancy) During the DUR process, manually check the patient's profile for medications and health conditions which may not be included in the DUR software. (reminder & checklist)		
Similar labels, both manufactured by MGP; and look and packaging: both pint-size, plastic, amber-colored bottles with same- colored labeling	ΙΨ	Provide auxiliary warning labels with exaggerated fonts, or use other label enhancements on packages and storage bins of drugs with problematic names, packages, and labels. (standardization) Use shelf dividers to separate products with look-alike names/packaging in all storage areas, including refrigerators and narcotic cabinets. (standardization) Avoid stocking generic manufacturers who incorporate same size stock bottle, and label colors and fonts, in their complete product line. (rules and policy or constraint)		



Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed	
		Use labels with special precautions on the stock bottles of high-alert medications (those whose inadvertent dispensing could cause serious harm if used in error). (reminder & checklist)			
		Identify stock bottle labels that are ambiguous or unsafe, and contact manufacturer or discontinue stocking from this manufacturer if safety features cannot be adequately employed; in addition, report these hazardous labels to ISMP. (standardization)			
Staff entered NDC from stock bottle, not drug name on prescription order	IV, VIII	Prescriptions are dispensed using the original prescription order and the computer-generated drug label together. A pharmacist compares the label and product with the original prescription before drugs are dispensed to the patient. (standardization)			
		<i>Use technicians only in areas and functions for which they have documented training.</i> (standardization)			
		Pharmacists and technicians seek and receive ongoing information about medication errors occurring within the organization, error-prone situations, errors occurring in other pharmacies, and strategies to prevent such errors. (standardization)			
		During staff meetings, discuss potential medication errors and ways to avoid them. (education)			
		When errors occur, offer education and suggestions to all staff, not just the staff directly involved in the error. (education)			
Medication administrators in group home are not licensed and have no minimum level of	IX	Provide patients and caregivers with brand and generic names of their medications, the purpose of the medication, and the dosing and important adverse effects of their medication, orally and/or in writing. (education)			
education required to administer drugs, do not check patients' medication charts for accuracy, do not know		When dispensing oral liquid medications for children or geriatric patients, a proper measuring device is provided (e.g., dropper) or suggested (e.g., oral syringe) and caregivers are instructed in its use to measure the prescribed dose. (standardization)			



Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed
common indications for drugs, do not check treatment		Insist on mandatory counseling to patients receiving high-alert medications or to patients considered to be high-risk. (standardization) Provide written information about their medications at a reading level that is comprehendible to patients. (education) Encourage personnel to develop and conduct at least one annual educational program or other proactive public health effort designed to improve safe use of medications in the community. (rules & policy)		
The drugs are stored alphabetically. The two drugs were in close proximity on the shelf (Lithium and Noctec); lighting in the "liquid section" was inadequate and stock bottles were crowded; there were no shelf dividers between products	₹, ¥11	Institute a "shelf talker" or sign program that brings attention to sound- and look-alike drug products during stocking and retrieval procedures. (standardization) Ensure adequate space, storage and lighting (10,000 ft candles) in medication stock and dispensing areas. (standardization)		



ISN	ISMP's Key Elements of the Medication Use System [™]				
I	Patient information				
П	Drug information				
ш	Communication of drug orders and other drug information				
IV	Drug labeling, packaging, and nomenclature				
V	Drug standardization, storage, and distribution				
VI	Medication device acquisition, use, and monitoring				
VII	Environmental factors, workflow and staffing patterns				
VIII	Staff competency and education				
IX	Patient education				
Х	Quality processes and risk management				

Case Study Example Two: Description

The Error (use Key Element table above to reference element numbers when assigning causative factor to *Assess-ERR*[™] tool)

A patient brought in a written prescription for ALDARA (imiquimod), to treat plantar warts, to her community pharmacy for filling and dispensing. After purchasing the product from the pharmacy associate, she sat down in the pharmacy waiting area to read the consumer medication information (CMI) sheet(s) as provided by the pharmacy, to ascertain if she might have any questions for the pharmacist before leaving the pharmacy. There was only one CMI sheet attached. She returned to the pharmacy counter to ask for the second, continuation, page of information. The directions on the pharmacy label indicated "Apply 4 times daily for 4 weeks." She then noticed that there were twelve "doses" of this cream provided by the package size dispensed with provision for 2 refills, for a total of 36 applications. With the dosage of 4 times daily, even with the refills, she realized that the medication would have "lasted" just 9 days-not the 4 weeks specified on the label. She went back to the pharmacy counter and asked to speak with the pharmacist. The pharmacist on duty took the prescription back to "check his records" and discovered that the correct dosage as written by the prescriber was "Apply four times per WEEK for 4 weeks." When the pharmacist returned the prescription to her with the corrected dosage label, he had simply attached the "new" one over the incorrect one. Because the patient was able to peel the correct one off to reveal the "overdose"/incorrect label, an error could occur with future at-home use if the "new" label became adulterated and peeled off.



Review of the Error

Consider where in the process the error occurred, consider contributing factors based on the previous modules, identify the key element (use Key Element table above to reference element numbers when assigning causative factor to $Assess-ERR^{TM}$ tool)

Process Step: Triage and Order Entry			
Contributing Factor	Key Element		
Legibility: prescription written "qw" misread as "qd"; inappropriate abbreviation used	III		
No indication for use on the prescription; patient not asked why medication was being prescribed	I, III		
Data entry by technician not familiar with product or dosing instructions	VIII		
Prescriber not contacted to verify illegible directions	III		

Process Step: Pharmacist Verification I			
Contributing Factor	Key Element		
Pharmacist did not have online reference available to check drug dosing	II		
Computer did not screen for maximum daily dose exceeded	II		
Order not verified by comparing data entry information to original prescription order	Ι		

Process Step: Product Pick (Selection)				
Contributing Factor	Key Element			
Unit-of-use product had manufacturer's instructions that were not read by staff and compared to pharmacy label instructions	IV, VIII			
Second (correct) label was placed on top of incorrect label, and incorrect label was allowed to remain on final dispensed product	V			



Process Step: Pharmacist Verification II				
Contributing Factor	Key Element			
Medication not checked against label and original order before dispensing	VIII			
Magnifiers not available to read hard copy prescriptions	VII			
Pharmacist did not verify dosing instructions to product information	II			

Process Step: Transfer to Will-Call Area			
Contributing Factor	Key Element		
CMI not completely dispensed to patient (2 nd page was "thrown out" by pharmacy associate because it made the receipt "too bulky")	IX		
Pharmacists accumulate demerits or points for making dispensing errors, so error "covered up" and not reported	Х		
Pick-up area too crowded; complete CMIs not always given, in order to reduce area needed for storage	VII		

Process Step: Point of Sale	
Contributing Factor	Key Element
Offer to counsel not made in a positive manner	VIII, IX
CMI not completely dispensed to patient	Х



Assess-ERR[™] tool completed for Example Two

Assess-ERR™ Community Pharmacy version

Medication System Worksheet Example Two

Rx # <u>1234</u>				
Date of error: 5-0	Date informat 09-09 obtained:	tion 5-10-09	Patier age:	nt 42
Drug(s) involved error:	l in			
STEP 1				
Was indication for prescription?	or use on the		⊠Yes	□ No
electronically?		1 - 1	□ Yes	⊠ No
pickup?	patient identifiers used	1 81	⊠Yes	□ No
counsel?			⊠Yes	□ No
Was the prescrib	oer notified		⊠Yes	
of the incident?	f the event (what when a	and	□ Yes	⊠ No
why): Prescription for Aldara cream labeled, with				
directions on the pharmacy label indicating "Apply 4 times daily for 4 weeks." Correct dosage as written b				
the prescriber was "	Apply four times per WEEK for	or 4 weeks"		

STEP 2

Key Element	Possible Causes	Y/N	Comments
I	Critical patient information missing? (age, weight, allergies, pregnancy, patient identity, address, indication for use, etc.)	Y	No indication for use on the prescription; patient not asked why medication was being prescribed Order not verified by comparing data entry information to original prescription order



Key Element	Possible Causes	Y/N	Comments
11	Critical drug information missing? (outdated/absent references, inadequate computer alerts, independent checks for high-alert drugs/high-risk patient, etc.)	Y	Pharmacist did not have online reference available to check drug dosing; computer did not screen for maximum daily dose exceeded Pharmacist did not verify dosing instructions to product information
111	Miscommunication of drug order? (illegible, ambiguous, incomplete, misheard, or misunderstood spoken rx, poor fax, unable to clarify with prescriber, etc.)	Y	Legibility: prescription written "qw" misread as "qd"; inappropriate abbreviation used Prescriber not contacted to verify illegible directions
IV	Drug name, label, packaging problem? (look-/sound-alike names, look-alike packaging, no drug image ,NDC or barcode not available or not used, etc.)	Y	Unit-of-use product had manufacturer's instructions that were not read by staff and compared to pharmacy label instructions Second (correct) label was placed on top of incorrect label, and incorrect label was allowed to remain on final dispensed product Pharmacist did not verify dosing instructions to product information
v	Drug storage or delivery problem? (drug stocked incorrectly, stock on crowded shelves, look-alike products stored next to each other, etc.)	Υ	Pick-up area too crowded; complete CMIs not always given in order to reduce area needed for storage
VI	Drug delivery device problem? (automated dispensing devices not calibrated or maintained, oral measuring device not dispensed, etc.)	Ν	
VII	Environmental, staffing, or workflow problems? (poor lighting, excessive noise, clutter, interruptions, human factors, workload, inefficient workflow, breaks not scheduled, etc.)	Y	Magnifiers not available to read hard copy prescriptions Pick-up area too crowded
VIII	Lack of staff education? (competency validation, new or unfamiliar drugs/devices, orientation process, feedback about errors/prevention, etc.)	Υ	Data entry by technician not familiar with product or dosing instructions Medication not checked against label and original order before dispensing
IX	Patient education	Y	CMI not completely dispensed to patient (2 nd page was



Key Element	Possible Causes	Y/N	Comments
	problem? (lack of information, non- adherence, not encouraged to ask questions, lack of investigating patient inquiries, patient barriers, etc.)		"thrown out" by pharmacy associate because it made the receipt "too bulky")
х	Quality processes and risk management? (No culture of safety, fear of error reporting, system- based causes not analyzed, independent double-check not performed, etc.)	Y	Pharmacists accumulate demerits or points for making dispensing errors, so error "covered up" and not reported

Patient

Outcome:

Error caught by patient at check out and corrected by pharmacy staff on duty

STEP 3

As a team, identify, prioritize and record "Identified Problem" from the "Comment" section in Step 2. Using the specific key element for those comments, refer to the recommendation strategies chart and select the most appropriate and effective interventions. Write selected strategies in the "Interventions Implemented" column below. This table will be used to document medication safety activities. Recommended interventions should address breakdowns in the *Key Elements* identified during event investigation. The staff should reconvene in three months time to determine if the proposed strategies have been implemented, if they are still pertinent, and if other strategies, as found in Appendix 4, to help generate appropriate interventions.

Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed
Pharmacist did not have online reference available to check drug dosing Pharmacist not aware of how often drug/device was to be used Pharmacist did not verify dosing instructions to product information	Π	The most current electronic drug references are available in the pharmacy; all outdated paper references are thrown out or taken home by staff. (education) Provide pharmacy staff with access to drug information center staffed with clinical pharmacists during all hours of operation. (redundancy)		



Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed
Computer did not screen for maximum daily dose exceeded	Π	Configure the pharmacy computer system to offer alerts for maximum and minimum doses of medications, drug interactions, age, allergies and dose-related interactions. (forcing functions)		
Pharmacist did not verify dosing instructions to product information	11, IV	Provide easy access to online drug information at every computer terminal. Provide an easy access icon, so the link to on-line information is readily accessible. (education) When dispensing unit-of-use packaging to patients, avoid placing pharmacy label on top of pertinent manufacturer's information. (rules & policy)		
		Prescriptions are dispensed using the original prescription order and the computer-generated drug label together. A pharmacist compares the label and product with the original prescription before drugs are dispensed to the patient. (standardization)		
Legibility: prescription written "qw" misread as "qd"; inappropriate abbreviation used; prescriber not contacted to verify illegible directions	III	Instruct staff never to use error-prone abbreviations or error-prone dose designations (trailing zeros and lack of leading zeros), drug name abbreviations or abbreviated sig codes when reducing oral prescriptions to writing. (rules & policy) Immediately call prescribers when prescriptions are written illegibly or ambiguously; confirm prescriptions written with error-prone abbreviations with either prescriber or patient; do not fill the prescription until the order is confirmed. (redundancy) Incorporate the use of scanning procedures so that original prescriptions can be viewed during each refill process. (automation & computerization)		
Pick-up area too crowded; complete CMIs not always given in order to reduce area needed for storage	V, VII	Maintain a prescription pick-up/will-call area that is free from clutter, and contains enough space to prevent "spillage" into the next basket or bin, and institute a return to stock program that physically removes filled prescriptions not picked up within seven days. (rules & policy)		



Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed
		Institute "Return to Stock" procedures that include contacting the patient to pick up filled prescription. (standardization)		
		Maintain separate refrigerators for stock and prepared prescriptions waiting to be dispensed (standardization)		
		Ensure adequate space, storage and lighting (10,000 ft candles) in medication stock and dispensing areas. (standardization)		
Data entry by technician not familiar with	VIII	Use technicians only in areas and for functions for which they have documented training. (standardization)		
product or dosing instructions Medication not checked against label and original order before		Pharmacists and technicians seek and receive ongoing information about medication errors occurring within the organization, error-prone situations, errors occurring in other pharmacies, and strategies to prevent such errors. (education)		
aispensing		Provide practice site, competency-based orientation regarding stocking, dispensing, preparation, verifying and delivery procedures to all newly hired staff. (education)		
		Evaluate each staff member's skills and knowledge regarding safe medication practices during annual employment review; address at- risk behaviors (<u>www.justculture.org</u>) on an ongoing basis. (education)		
		When errors occur, educational efforts are widespread among all pharmacy personnel who may make a similar error, rather than remedial and directed at only those who were involved in an error. (education)		



Conclusion

Systematic assessment of error prevention is vital to safety. It is not enough for pharmacy practitioners and operators to simply strive to prevent error. To maximize safety, pharmacists at all levels must also strive to *learn* from those errors that have occurred. It may be fair to say that the most egregious error made in a pharmacy is one that has been made before.

The educational modules introduced here have been designed to heighten awareness of potential failures in the medication-use system and identify distinctive characteristics of safe pharmacy systems. Knowledge gained by completing these modules will help pharmacy staff identify and evaluate potential risk-reduction strategies. Additionally, the modules will assist pharmacy staff to assess the degree to which safe practices already have been implemented in their settings, and to assess the degree to which the practices provide tangible evidence of patient safety improvement and increased patient satisfaction and loyalty. These tools are to be used by pharmacy staff to proactively review the safety of their practice site and their own knowledge of contributing factors of errors, and to take action to continually improve the safety and thus the quality of care they provide. Implementation of these tools will improve patient safety.



Acknowledgements

FUNDING SOURCE

We thank the National Association of Chain Drug Stores Foundation and AstraZeneca Medical Education Grants for providing financial support for the ISMP assessment tool *Improving Medication Safety in Community Pharmacy: Assessing Risk and Opportunities for Change*.

ADVISORY BOARD

ISMP would like to recognize the following members of our volunteer Advisory Board, who helped review the content of the ISMP assessment tool *Improving Medication Safety in Community Pharmacy: Assessing Risk and Opportunities for Change*.

Mary E. Burkhardt, MS, RPh, FASHP
Director of Medication Safety
Medco Health Solutions
Belleville, MI

Joanne Doyle Petrongolo, PharmD Massachusetts General Hospital Boston, MA

Deborah J. Faucette, RPh Consultant

Rick Geaney, RPh, CDM

Pharmacy Market Manager Rite-Aid Pharmacy Stratham, NH

Susan Jacobson, EdD, RPh Asst. Professor of Pharmacy Practice Massachusetts College of Pharmacy and Health Sciences Boston, MA

Tim R. Koch, RPh Director, Pharmacy Regulatory Affairs Wal-Mart Health and Wellness Division

Debbie Mack, RPh

Director of Pharmacy Regulatory Affairs Walmart Health and Wellness Division Bentonville, AR

Sophie McIntyre, PharmD Director of Clinical Services

Eaton Apothecary Holliston, MA

Andrew C. Seger, PharmD

Senior Research Pharmacist Division of General Medicine and Primary Care Brigham & Women's Hospital Boston, MA

Consultant Pharmacist Center for Patient Safety Dana-Farber Cancer Institute Boston, MA

Clinical & Quality Analysis Partners HealthCare Systems, Inc. Wellesley,MA

Ray Seidlinger, RPh

Inspector Nevada State Board of Pharmacy Las Vegas, NV

Edward J. Staffa, RPh Silver Spring, MD

Joanne M. Trifone, RPh

President-Elect Massachusetts Board of Pharmacy Walgreens Staff Pharmacist Dorchester, MA

Eleanor M. Vogt RPh, PhD

Professor Univ. of California San Francisco School of Pharmacy San Francisco, CA

Bentonville, AR



PILOT PHASE PARTICIPANTS

ISMP would also like to recognize the following individuals and practice sites for their time involved in voluntarily piloting and commenting on the content of the ISMP assessment tool *Improving Medication Safety in Community Pharmacy: Assessing Risk and Opportunities for Change*.

Susan Beck, PharmD Pharmacy Manager Walmart Pharmacy 10-1039 Mount Airy, NC

Yuliya Bratnikov, PharmD Eaton Apothecary Holliston, MA

Lori C. Brown, PharmD Director of Clinical Operations KDI Health Solutions

Manager of Clinical Services Kerr Drug Asheville, NC

Carlos Dominguez, PharmD Candidate Northeastern University Boston, MA

Julia Eaton, RPh Staff Pharmacist Walmart Pharmacy 10-2530 Rutland, VT

Dan Krinsky, MS, RPh

Assistant Clinical Professor Northeastern Ohio Universities College of Medicine & Pharmacy Rootstown, OH

Manager, MTM Services Giant Eagle Pharmacy Ravenna, OH

Nirali Rana, PharmD

Pharmacy Manager Walgreens Arlington, MA

Joanne M. Trifone, RPh

President-Elect Massachusetts Board of Pharmacy Walgreens Staff Pharmacist Dorchester, MA



References

¹ Aspden P, Wolcott JA, Bootman JL, et al, eds. *Preventing medication errors: Quality chasm series*. Washington, DC: The National Academies Press; 2006. ² Institute for Safe Medication Practices. Spotlight on the key elements of the medication system. *ISMP Medication Safety Alert! Community/Ambulatory Care Edition*. 2003; 2(10): 3-4.

³ Institute for Safe Medication Practices. Spotlight on the key elements of the medication system - part 2. *ISMP Medication Safety Alert! Community/Ambulatory Care Edition*. 2003;10(11):3-4.

⁴ Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. *JAMA*. 1995;274(1):35-43.

⁵ Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. *JAMA*. 1997;277(4):312-7.

⁶ Johnston D, Pan E., Middleton B, et al. The value of computerized order entry in ambulatory settings. Boston, MA: Center for Information Technology Leadership; 2004.

⁷ Institute for Safe Medication Practices. Safety brief. *ISMP Medication Safety Alert!* 2000;5(15):1.

⁸ US Department of Health and Human Services. *Pilot testing of initial electronic prescribing standards – Cooperative agreements required under section 1860D-(4) (e) of the Social Security Act as amended by the Medicare Prescription Drug, Improvement, and Modernization Action (MMA) of 2003.* Washington, DC: US Dept of Health and Human Services; 2007. <u>http://healthit.ahrq.gov/portal/server.pt/gateway/PTARGS 0 1248 227312 0 0 18/eRxReport 041607.pdf</u>. Accessed February 13, 2009.

⁹ Institute for Safe Medication Practices. Practitioners speak up about this unresolved problem – part 1. *ISMP Medication Safety Alert!* 2003;9(5):1-3.

¹⁰ Grasha AF, Reilley S, Schell KL, et al. Delayed verification errors in community pharmacy. Technical Report Number 112101. Cincinnati, Ohio: Cognitive Systems Performance Laboratory. 2000.

¹¹ Cohen MR, ed. *Medication errors*. 2nd ed. Washington, DC: American Pharmacists Association; 2006.

¹² National Patient Safety Agency. Design for patient safety: A guide to the design of the dispensing environment. London, UK: National Patient Safety Agency; 2007. <u>http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=11293</u>. Accessed February 13, 2009.

¹³ Filik R, Purdy K, Gale A, et al. Drug name confusion: evaluating the effectiveness of capital ("Tall Man") letters using eye movement data. *Social Science & Medicine* 2004;59(12):2597-2601.

¹⁴ Filik R, Purdy K, Gale A, et al. Labeling of medicines and patient safety: evaluating methods of reducing drug name confusion. *Human Factors* 2006; 48(1): 39-47.



¹⁵ Grasha A. Cognitive systems perspective on human performance in the pharmacy: implications for accuracy, effectiveness, and job satisfaction (Report No. 062100). Alexandria, VA: NACDS. 2000.

¹⁶ Simons FER, Lieberman PL, Read EJ, Edwards ES. Hazards of unintentional injection of epinephrine from auto injectors: a systematic review. *Ann Allergy Asthma Immunol* 2009;102:267-272.

¹⁷ Buchanan TL, Barker KN, Gibson JT, et al. Illumination and errors in dispensing. *Am J Health-Syst Pharm*. 1991;48(10):2137-2145.

¹⁸ Grasha, AF. Misconceptions about workload. *Canadian Pharmaceutical Journal*. April 2001.

¹⁹ ConsumerMedSafety.org. Institute for Safe Medication Practices Web site. <u>http://www.consumermedsafety.org</u>. Accessed February 13, 2009.

²⁰ Rados C. Drug name confusion: preventing medication errors. *FDA Consumer*. 2005; 39(4).

²¹ Moray, Neville. Error reduction as a systems problem. In: Bogner MS, ed. *Human error in medicine*. Hillsdale, NJ: Lawrence Erlbaum Associates; 1994:67-91.



Glossary

<u>Administration Error</u>: Medication dosages that are given to the patient in error, usually by the direct caregiver.

<u>At-Risk Behavior</u>: Behavioral choices that increase risk where risk is not recognized, or is mistakenly believed to be justified; emerge because of system-based problems such as complexity, understaffing, rushing, problems with technology, etc.

<u>Basket System</u>: A container system that separates orders to be filled by patient and can include a written prescription, printed material provided by a computer printer in response to data input including the patient specific label, stock bottle of medication to be dispensed or the completely labeled and filled prescription vial(s) for one patient; the basket system also sets the stage for the workflow by identifying whether a customer is waiting or not.

<u>Culture of Safety</u>: An atmosphere of mutual trust in which all staff members can talk freely about safety problems and how to solve them, without fear of reprisal.

<u>Competency Validation</u>: The process of ensuring that staff possesses the skill set identified in his or her job description, and performs the tasks or activities for the position according to established standards.

<u>Dispensing Error</u>: Deviations from the prescriber's order, made by staff in the pharmacy when distributing medication to nursing units or to patients in ambulatory settings.

<u>Failure Mode and Effects Analysis (FMEA)</u>: A proactive process to identify potential errors and determine possible effects; a team-based, systematic approach. Identify the ways that a process or design: can fail, why it might fail, what will happen if it fails, and how it can be made safer.

Because of its proactive nature, FMEA and other risk assessment tools are the focus of these modules.

<u>Filters</u>: A device or program that allows passage of some signals but not others. In relation to pharmacy, being put on "filter" refers to an order screening process or training tool where orders processed by new or inexperienced employees, or employees having difficulty focusing due to personal issues such as illness or death of a loved one, are systematically passed by or routed to an experienced employee for approval or oversight before being sent for further processing.

<u>High-alert Medication</u>: Drugs that bear a heightened risk of causing significant patient harm when they are prescribed, dispensed, administered or used in error;



such medications in community pharmacy may include warfarin, insulin, fentanyl patches and methotrexate.

<u>High-Leverage Safety Strategies</u>: Safety strategies that have the ability to consistently impact safety because they are not dependent on human vigilance to be successful; strategies such as forcing functions, fail-safes, and constraints.

<u>Human Factors</u>: An umbrella term for several areas of research that include human performance, technology design, and human-computer interaction (engineering). This area of knowledge deals with the capabilities and limitations of human performance in relation to design of machines, jobs, and other modifications of the human's physical environment; also known as human engineering. Often referred to as "ergonomics", this field includes, but is not limited to ergonomics.

<u>Just Culture</u>: An organizational model of accountability whereby a learning environment is established, and staff are encouraged to recognize and report safety hazards, design safe systems, and make safe behavioral choices.

<u>Just Culture Process and Algorithms</u>: Structured process to guide managers through the evaluation of an event, near miss, or simply the analysis of a risky behavior. It is a process for conducting an investigation of the event, for identifying system contributions, and for assessing accountability for those involved in the event. See <u>www.justculture.org/algorithm.aspx</u> for more information and training.

<u>Medication Error</u>: Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient or consumer. Such events may be related to professional practice; health care products; or procedures and systems including prescribing, order communication, product labeling, packaging and nomenclature; compounding, dispensing, distribution, administration, education, monitoring and use.

<u>Medication Therapy Management Services (MTMS)</u>: Services provided by pharmacists that improve treatment outcomes and promote the safe and effective use of medications; for more information go to <u>www.pharmacist.com/MTM</u>.

<u>Prescribing Error</u>: Mistakes made by the prescriber when ordering a medication (e.g., miscalculation of a dose, misspelling of a drug name, choosing the wrong product for the diagnosis).

<u>Root Cause Analysis (RCA)</u>: A process for identifying the basic or causal factors that underlie variation in performance, including the occurrence or risk of occurrence of a sentinel event or adverse event. RCA is a retrospective investigative process that teaches us what went wrong within any given process.



As a tool, RCA is designed to:

- describe *what* happened during a particular occurrence;
- determine *how* it happened;
- understand *why* it happened; and
- recommend actions to *prevent* it from happening again.

Root cause analysis is an essential process to use after an error or sentinel event has occurred. However, providers and clinicians realize that when they're dealing with human life, a prospective strategy for identifying risk is preferred.

<u>Shared Accountability</u>: All members of the organization, executives, managers and staff, will work together toward the organization's mission of quality patient care and safe practices. Both the rewards of success and losses associated with failure will be shared by the entire executive team, managers and staff.

<u>Slip</u>: An error at the (task) execution stage of cognition; to mentally fall into fault or error. Usually used with "up". Example is putting the cereal back in the refrigerator and the milk away in the cupboard.

<u>Teach Back Method</u>: A technique to check patient understanding and comprehension through a non-threatening approach, by asking patients to repeat *in their own words* what they need to do with medication and devices when they leave the pharmacy.



Appendix 1: ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations

ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations

The abbreviations, symbols, and dose designations found in this table have been reported to ISMP through the ISMP Medication Errors Reporting Program (MERP) as being frequently misinterpreted and involved in harmful medication errors. They should NEVER be used when communicating medical information. This includes internal communications, telephone/verbal prescriptions, computer-generated labels, labels for drug storage bins, medication administration records, as well as pharmacy and prescriber computer order entry screens.

The Joint Commission (TJC) has established a National Patient Safety Goal that specifies that certain abbreviations must appear on an accredited organization's do-not-use list; we have highlighted these items with a double asterisk (**). However, we hope that you will consider others beyond the minimum TJC requirements. By using and promoting safe practices and by educating one another about hazards, we can better protect our patients.

Abbreviations	Intended Meaning	Misinterpretation	Correction
μg	Microgram	Mistaken as "mg"	Use "mcg"
AD, AS, AU	Right ear, left ear, each ear	Mistaken as OD, OS, OU (right eye, left eye, each eye)	Use "right ear," "left ear," or "each ear"
OD, OS, OU	Right eye, left eye, each eye	Mistaken as AD, AS, AU (right ear, left ear, each ear)	Use "right eye," "left eye," or "each eye"
BT	Bedtime	Mistaken as "BID" (twice daily)	Use "bedtime"
CC	Cubic centimeters	Mistaken as "u" (units)	Use "mL"
D/C	Discharge or discontinue	Premature discontinuation of medications if D/C (intended to mean "discharge") has been misinterpreted as "discontinued" when followed by a list of discharge medications	Use "discharge" and "discontinue"
IJ	Injection	Mistaken as "IV" or "intrajugular"	Use "injection"
IN	Intranasal	Mistaken as "IM" or "IV"	Use "intranasal" or "NAS"
HS	Half-strength	Mistaken as bedtime	Use "half-strength" or "bedtime"
hs	At bedtime, hours of sleep	Mistaken as half-strength	
IU**	International unit	Mistaken as IV (intravenous) or 10 (ten)	Use "units"
o.d. or OD	Once daily	Mistaken as "right eye" (OD-oculus dexter), leading to oral liquid medications administered in the eye	Use "daily"
OJ	Orange juice	Mistaken as OD or OS (right or left eye); drugs meant to be diluted in orange juice may be given in the eye	Use "orange juice"
Per os	By mouth, orally	The "os" can be mistaken as "left eye" (OS-oculus sinister)	Use "PO," "by mouth," or "orally"
q.d. or QD**	Every day	Mistaken as q.i.d., especially if the period after the "q" or the tail of the "q" is misunderstood as an "i"	Use "daily"
qhs	Nightly at bedtime	Mistaken as "qhr" or every hour	Use "nightly"
qn	Nightly or at bedtime	Mistaken as "qh" (every hour)	Use "nightly" or "at bedtime"
q.o.d. or QOD**	Every other day	Mistaken as "q.d." (daily) or "q.i.d. (four times daily) if the "o" is poorly written	Use "every other day"
q1d	Daily	Mistaken as q.i.d. (four times daily)	Use "daily"
q6PM, etc.	Every evening at 6 PM	Mistaken as every 6 hours	Use "6 PM nightly" or "6 PM daily"
SC, SQ, sub q	Subcutaneous	SC mistaken as SL (sublingual); SQ mistaken as "5 every;" the "q" in "sub q" has been mistaken as "every" (e.g., a heparin dose ordered "sub q 2 hours before surgery" misunderstood as every 2 hours before surgery)	Use "subcut" or "subcutaneously"
SS	Sliding scale (insulin) or ½ (apothecary)	Mistaken as "55"	Spell out "sliding scale;" use "one-half" or "1/2"
SSRI	Sliding scale regular insulin	Mistaken as selective-serotonin reuptake inhibitor	Spell out "sliding scale (insulin)"
SSI	Sliding scale insulin	Mistaken as Strong Solution of Iodine (Lugol's)	
ī/d	One daily	Mistaken as "tid"	Use "1 daily"
TIW or tiw	3 times a week	Mistaken as "3 times a day" or "twice in a week"	Use "3 times weekly"
U or u**	Unit	Mistaken as the number 0 or 4, causing a 10-fold overdose or greater (e.g., 4U seen as "40" or 4u seen as "44"); mistaken as "cc" so dose given in volume instead of units (e.g., 4u seen as 4cc)	Use "unit"
Dose Designations and Other Information	Intended Meaning	Misinterpretation	Correction
Trailing zero after decimal point (e.g., 1.0 mg)**	1 mg	Mistaken as 10 mg if the decimal point is not seen	Do not use trailing zeros for doses expressed in whole numbers"
"Naked" decimal point (e.g., .5 mg)**	0.5 mg	Mistaken as 5 mg if the decimal point is not seen	Use zero before a decimal point when the dose is less than a whole unit

Dose Designations and Other Information	Intended Meaning	Misinterpretation	Correction
Drug name and dose run	Inderal 40 mg	Mistaken as Inderal 140 mg	Place adequate space between the drug
together (especially problematic for drug	Tearetal 300 ma	Mistaken as Tegretol 1300 mg	name, dose, and unit of measure
names that end in "I"			
such as Inderal40 mg; Tegretol300 mg)			
Numerical dose and unit	10 mg	The "m" is sometimes mistaken as a zero or two zeros risking a	Place adequate snace between the dose and
of measure run together	lo ing	10- to 100-fold overdose	unit of measure
(e.g., 10mg, 100mL)	100 mL		
Abbreviations such as mg.	mg	The period is unnecessary and could be mistaken as the number	Use mg, mL, etc. without a terminal period
or mL. with a period	ml		
וטווטשוווט נוכ מטטוביומנוטוו			
Large doses without	100,000 units	100000 has been mistaken as 10,000 or 1,000,000; 1000000 has	Use commas for dosing units at or above
(e.g., 100000 units;	1,000,000 units		1,000, or use words such as 100 "thousand"
1000000 units)			
Drug Name Abbreviations	Intended Meaning	Misinterpretation	Correction
ARA A	vidarabine	Mistaken as cytarabine (ARA C)	Use complete drug name
AZT	zidovudine (Retrovir)	Mistaken as azathioprine or aztreonam	Use complete drug name
CPZ	Compazine (prochlorperazine)	Mistaken as chlorpromazine	Use complete drug name
DPT	Demerol-Phenergan-Thorazine	Mistaken as diphtheria-pertussis-tetanus (vaccine)	Use complete drug name
DTO	Diluted tincture of opium, or deadarized tincture of opium	Mistaken as tincture of opium	Use complete drug name
	(Paregoric)		
HCI	hydrochloric acid or	Mistaken as potassium chloride	Use complete drug name unless expressed
	hydrochloride	(The "H" is misinterpreted as "K")	as a salt of a drug
HUI	hydrocortisone	Mistaken as hydrochlorothiazide	Use complete drug name
HUIZ	hydrochlorothiazide	Mistaken as hydrocortisone (seen as HC1250 mg)	Use complete drug name
MG5U4***	magnesium suitate	Mistaken as morphine suifate	Use complete drug name
INI5, INI5U4""	morphine suitate	Mistaken as magnesium suitate	Use complete drug name
	nregginemide	Mistaken as nationt controlled analysis	Use complete drug name
PUA DTII	propulthiourooil	Mistaken as patient controlleu analgesia	
	Tylepol with codeine No. 3	Mistaken as lietopupuline	
	triamcinolone	Mistakon as totracaine. Adrenalin, cocaine	
TNK	TNKase	Mistakon as "TDA"	
7n\$04	zine sulfate	Mistaken as mornhine sulfate	Use complete drug name
Stemmed Drug Names	Intended Meaning	Misinterpretation	Correction
"Nitro" drip	nitroalycerin infusion	Mistaken as sodium nitroprusside infusion	Use complete drug name
"Norflox"	norfloxacin	Mistaken as Norflex	Use complete drug name
"IV Vanc"	intravenous vancomvcin	Mistaken as Invanz	Use complete drug name
Symbols	Intended Meaning	Misinterpretation	Correction
3	Dram	Symbol for dram mistaken as "3"	Use the metric system
m	Minim	Symbol for minim mistaken as "ml"	-
x3d	For three days	Mistaken as "3 doses"	Use "for three days"
> and <	Greater than and less than	Mistaken as opposite of intended: mistakenly use incorrect	Use "greater than" or "less than"
		symbol; "< 10" mistaken as "40"	
/ (slash mark)	Separates two doses or indicates "ner"	Mistaken as the number 1 (e.g., "25 units/10 units" misread as "25 units and 110" units)	Use "per" rather than a slash mark to separate doses
@	At	Mistaken as "2"	Use "at"
<u> </u>	And	Mistaken as "2"	Use "and"
+	Plus or and	Mistaken as "4"	Use "and"
0	Hour	Mistaken as a zero (e.g., g2° seen as ɑ 20)	Use "hr," "h," or "hour"

ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations (continued)

**These abbreviations are included on TJC's "minimum list" of dangerous abbreviations, acronyms and symbols that must be included on an organization's "Do Not Use" list, effective January 1, 2004. Visit www.jointcommission.org for more information about this TJC requirement.

Permission is granted to reproduce material for <u>internal</u> newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.ismp.org</u> or by calling 1-800-FAIL-SAF(E). ISMP guarantees confidentiality of information received and respects reporters' wishes as to the level of detail included in publications.

Institute for Safe Medication Practices www.ismp.org


Appendix 2: FDA and ISMP Lists of Look-Alike Drug Name Sets with Recommended Tall Man Letters

FDA and ISMP Lists of Look-Alike Drug Name Sets With Recommended Tall Man Letters

he sets of look-alike drug names in the Tables below have been modified using "tall man" letters to help draw attention to the dissimilarities in their names. Several studies have shown that highlighting sections of drug names using tall man (mixed case) letters can help distinguish similar drug names,¹ making them less prone to mix-ups.²⁻³ ISMP, FDA, The Joint Commission, and other safetyconscious organizations have promoted the use of tall man letters as one means of reducing confusion between similar drug names.

 Table 1 provides a list of FDA-approved established drug name sets

 with recommended tall man letters, which were first identified during

 the FDA Name Differentiation Project (www.fda.gov/CDER/Drug/

 MedErrors/nameDiff.htm).

 Table 2 provides a list of additional drug name sets with recommendations from ISMP regarding the use and placement of tall man letters.

 This is not an official list approved by FDA. It is intended for voluntary use by healthcare practitioners and drug information vendors. Any product label changes by manufacturers require FDA approval.

Table 1. FDA-Approved List of Established Drug Names with Tall Man Letters			
acetoHEXAMIDE - acetaZOLAMIDE	hydr ALAZINE – hydr OXY zine		
bu PROP ion - bus PIR one			
chlorpro MAZINE – chlorpro PAMIDE	methylPREDNISolone		
clomi PHENE – clomi PRAMINE			
cycloSPORINE - cycloSERINE	ni CAR dipine – NIFEdipine		
DAUNOrubicin – DOXOrubicin	predniSONE – prednisoLONE		
dimenhy DRINATE – diphenhydr AMINE	sulfADIAZINE – sulfiSOXAZOLE		
DOBUTamine – DOPamine	TOLAZamide – TOLBUTamide		
glipi ZIDE – gly BURIDE	vinBLAStine – vinCRIStine		

References: 1) Filik R, Purdy K, Gale A, Gerrett D. Drug name confusion: evaluating the effectiveness of capital ("Tall Man") letters using eye movement data. *Social Science & Medicine* 2004;59(12):2597-2601. **2)** Filik R, Purdy K, Gale A, Gerrett D. Labeling of medicines and patient safety: evaluating methods of reducing drug name confusion. *Human Factors* 2006;48(1):39-47. **3)** Grasha A. Cognitive systems perspective on human performance in the pharmacy: implications for accuracy, effectiveness, and job satisfaction. Alexandria (VA): NACDS; 2000 Report No. 062100. One of the difficulties with the use of tall man letters is the lack of scientific evidence regarding which name pairs would most benefit from this error-reduction strategy as well as which letters to present in uppercase. Until further evidence is available, ISMP suggests that the tall man lettering scheme provided in these Tables be followed to promote consistency.

Table 2. ISMP List of Additional Drug Names with Tall Man Letters				
ALPRAZolam - LORazepam	metroNIDAZOLE - metFORMIN			
am LODIP ine – a MIL oride	morphine – HYDRO morphone			
aza CITID ine – aza THIO prine	NexIUM*- NexAVAR*			
ce FAZ olin – cef TRIAX one	ni MOD ipine – NIFEdipine			
Cele BREX * – CeleXA*	NovoLOG* – NovoLIN*			
chlorpro MAZINE – chlordiaze POXIDE	OXcarbazepine – carBAMazepine			
CISplatin – CARBOplatin	oxy CODONE – Oxy CONTIN*			
clonaze PAM – cloNIDine	PARoxetine – FLUoxetine			
clonaze PAM - LOR azepam	PENT obarbital – PHEN obarbital			
cloNIDine – KlonoPIN*	Pri LOSEC* – PRO zac*			
DACTINomycin – DAPTOmycin	QUEtiapine – OLANZapine			
ePHEDrine – EPINEPHrine	quiNINE – quiNIDine			
fenta NYL - SUF entanil	ri TUX imab in FLIX imab			
FLUoxetine – DULoxetine	SandIMMUNE* - SandoSTATIN*			
guan FACINE – guai FEN esin	SEROquel* - SINEquan*			
Huma LOG* – Humu LIN*	Solu-MEDROL* - Solu-CORTEF*			
HYDROcodone – oxyCODONE	SUMAtriptan – sitaGLIPtin			
IDArubicin – DOXOrubicin	ti ZAN idine - tia GAB ine			
INVanz* – AVINza*	tra ZOD one - tra MAD ol			
La MIC tal* – Lam ISIL *	TRENtal – TEGretol*			
lami VUD ine – lamo TRI gine	Zy prexa * – Zyr tec*			

* Brand names always start with an uppercase letter. Some brand names incorporate tall man letters in initial characters and may not be readily recognized as brand names. An asterisk follows all brand names in Table 2.

© ISMP 2008. Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission from ISMP. Report actual and potential medication errors to the Medication Errors Reporting Program (MERP) via the Web at www.ismp.org or by calling 1-800-FAIL-SAF(E).





Appendix 3: Assess-ERR[™] (Community Pharmacy Version)

The Assess-ERR[™] Medication System Worksheet for community pharmacy can be found on the following three pages. Use this worksheet to collect initial error information, guide event investigation, and focus risk-reduction strategies. A Microsoft Word version is available at: <u>www.ismp.org/Tools/Community_AssessErr</u>.

Assess-ERRTM Community Pharmacy Version

Medication System Worksheet

Rx #		
Date of error:	Date information obtained:	
Patient age:		
Drug(s) involved in error:		
STEP 1		
Was indication for use on the prescription?	🗆 Yes	🗆 No
Was the prescription obtained electronically?	🗆 Yes	🗆 No
Were two unique patient identifiers used at pick	xup? □ Yes	🗆 No
Did the patient accept the offer to counsel?	🗆 Yes	🗆 No
Did the error reach the patient?	□ Yes	🗆 No
Was the prescriber notified of the incident?	□ Yes	🗆 No
Brief description of the event (what, when, and	why):	

STEP 2

Key Element	Possible Causes	Y/N	Comments
I	Critical patient information missing? (e.g., age, weight, allergies, pregnancy, patient identity, address, indication for use)		
11	Critical drug information missing? (e.g., outdated/absent references, inadequate computer alerts, independent checks for high-alert drugs/high-risk patient)		
111	Miscommunication of drug order? (e.g., illegible, ambiguous, incomplete, misheard, or misunderstood spoken rx, poor fax, unable to clarify with prescriber)		
IV	Drug name, label, packaging problem? (e.g., look- and sound-alike names, look-alike packaging, no drug image, NDC or barcode not available or not used)		

Key Element	Possible Causes	Y/N	Comments
v	Drug storage or delivery problem? (e.g., drug stocked incorrectly, stock on crowded shelves, look-alike products stored next to each other)		
VI	Drug delivery device problem? (e.g., automated dispensing devices not calibrated or maintained, oral measuring device not dispensed)		
VII	Environmental, staffing, or workflow problems? (e.g., poor lighting, excessive noise, clutter, interruptions, human factors, workload, inefficient workflow, breaks not scheduled)		
VIII	Lack of staff education? (e.g., competency validation, new or unfamiliar drugs/devices, orientation process, feedback about errors/prevention)		
IX	Patient education problem? (e.g., lack of information, non-adherence, not encouraged to ask questions, lack of investigating patient inquiries, patient barriers)		
x	Quality processes and risk management? (e.g., no culture of safety, fear of error reporting, system-based causes not analyzed, independent double-check not performed)		

Patient Outcome:

Assess-ERRTM Community Pharmacy Version

Medication System Worksheet

STEP 3

As a team, identify, prioritize and record "Identified Problem" from the "Comment" section in Step 2. Using the specific key element for those comments, refer to the recommendation strategies chart and select the most appropriate and effective interventions. Write selected strategies in the "Interventions Implemented" column below. This table will be used to document medication safety activities. Recommended interventions should address breakdowns in the *Key Elements* identified during event investigation. The staff should reconvene in three months time to determine if the proposed strategies have been implemented, if they are still pertinent, and if other strategies have been offered or considered since the initial review. Use a variety of strategies, as found in Appendix 4, to help generate appropriate interventions.

Identified Problem (from Comments, above)	Key Element	Interventions Implemented	Person/Dept. Responsible for Follow Up	Date Completed



Appendix 4: Strategies to be used with the Assess-ERR[™] (Community Pharmacy Version)

Use a variety of the following strategies to focus on system issues and human factors in order to continually enhance safety procedures in your pharmacy. Share this information with colleagues at your site and within your greater organization.

- Fail-safes and constraints involve true system changes in the design of products or how individuals interact within the system. When the pharmacy computer system is integrated with the cash register, a fail-safe would prevent the clerk from "ringing up" the prescription unless final verification by a pharmacist had occurred.
- Forcing functions are procedures that create a "hard stop" during a process to help ensure that important information is provided before proceeding. For example, a pharmacy computer system that prevents overriding selected high-alert messages without a notation (e.g., patient-specific indication must be entered if high-alert medication selected).
- Automation and computerization of medication-use processes can reduce reliance on memory. Examples include true electronic systems that can receive electronic prescriptions from a prescriber, thus eliminating data entry misinterpretation at the pharmacy; and robotic dispensing devices.
- **Standardization** creates a uniform model to adhere to when performing various functions and to reduce the complexity and variation of a specific process. For example, create standardized processes to guide the pharmacist's final verification of a medication or to enhance the safety of giving or receiving a telephoned medication order.
- **Redundancies** incorporate duplicate steps or add another individual to a process to force additional checks in the system. Involving two individuals in a process reduces the likelihood that both will make the same error with the same medication for the same patient. However, the potential for error still exists since the redundant step may be omitted or ignored. Examples include use of both brand and generic names when communicating medication information. Patient counseling is often an underutilized redundancy that can detect many errors.



- **Reminders and checklists** help make important information readily available. For example, prescription blanks that include prompts for important information (e.g., medication indication, allergies, patient birth date).
- **Rules and policies** are useful and necessary in organizations. Effective rules and policies should guide staff toward an intended positive outcome. However, some may add unnecessary complexity and may be met with resistance, especially when implemented in haste in response to an error. Because their use relies on memory, they should be used as a foundation to support other strategies that target system issues.
- Education and information are important tactics when combined with other strategies that strengthen the medication-use system. The effectiveness of these tactics relies on an individual's ability to remember what has been presented. Thus, on their own, they offer little leverage to prevent errors.





Appendix 5: Selected Data from ISMP Medication Safety Self Assessment[™] for Community/Ambulatory Pharmacy

The content of each module in the *Improving Medication Safety in Community Pharmacy: Assessing Risk and Opportunities for Change* (tool) was developed using national aggregate data collected from the *ISMP Medication Safety Self Assessment*^M *for Community/Ambulatory Pharmacy* (self assessment). The self assessment (<u>www.ismp.org/Survey/NewMssacap/Index.asp</u>) was developed and made available to community and ambulatory pharmacies in 2001 for the purpose of encouraging individual pharmacies to self evaluate their processes and look for opportunities for safety improvements. The *Assessment* is divided into sections that represent each *Key Element*. Participants were asked to score their success with each safety characteristic by entering their findings on ISMP's website using the following scoring key:

- **A**. There has been <u>no activity</u> to implement this characteristic in the pharmacy or for any patients, prescriptions, drugs, or staff.
- **B**. This characteristic has been <u>discussed for possible implementation</u> in the pharmacy, but is not implemented at this time.
- **C**. This characteristic has been <u>partially implemented</u> in the pharmacy for <u>some or</u> <u>all</u> patients, prescriptions, drugs, or staff.
- **D**. This characteristic has been <u>fully implemented</u> in the pharmacy for <u>some</u> patients, prescriptions, drugs, or staff.
- **E**. This characteristic has been <u>fully implemented</u> in the pharmacy for <u>all</u> patients, prescriptions, drugs, or staff.

In order to simplify the reported scores for use in these modules, the aggregate scores were bundled/categorized as:

- A and B = no implementation
- **C** and **D** = partial implementation
- **E** = full implementation



Selected examples of data collected

Specific items in self assessment - report of current activities: Patient Information

	Degree of Implementation		entation
	None	Partial	Full
When taking orders over the telephone, the prescriber (or designee) is specifically queried about co-morbid conditions, allergies, and the patient's weight.	62%	33%	5%
Prescription orders cannot be entered into the pharmacy computer system until the patient's allergies have been properly entered and coded (patient allergies is a required field).	84%		16%
The clinical purpose of each prescription is ascertained before the medication is dispensed to assure that the prescribed therapy is appropriate for the patient's condition and to help distinguish medications with similar packaging and look-alike or sound-alike names.	28%	52%	20%

Specific items in self assessment - report of current activities: Drug Information

	Degree of Implementation		entation
	None	Partial	Full
A designated pharmacist or corporate level staff routinely reviews, for quality improvement purposes, reports of computer warnings that are overridden by pharmacists.	51%	16%	32%
Pharmacy staff tests the computer system at least twice annually to assure that maximum dose alerts are present for high-alert and drugs with a narrow therapeutic index <u>and</u> builds alerts for those that are not present, or provides feedback to corporate level staff or drug information system vendors when appropriate.	67%	12%	22%



Specific items in self assessment - report of current activities: Communication

	Degree of Implementation		
	None	Partial	Full
A list of prohibited, dangerous abbreviations and error-prone dose designations is established for internal communication and documentation of prescription orders, computer systems and pharmacy labels.	55%	25%	20%
Feedback is provided, at least annually, to community physicians to educate them about unsafe prescription writing practices.	75%	15%	10%

Specific items in self assessment - report of current activities: Drug Packaging and Labeling

	Degree of Implementation		entation
	None	Partial	Full
Pharmacists regularly examine the package and label of new drugs to identify any potential for confusion.	23%	37%	40%
When two different products exist that have dangerously similar labeling/packaging, pharmacy seeks an alternate manufacturer for one of the products.	45%	30%	25%
Products with known look-alike drug names are stored separately and <u>not alphabetically</u> , or are <u>clearly differentiated</u> if they remain next to each other.	23%	38%	40%
Auxiliary warnings, labels with exaggerated fonts, or other label enhancements are used on packages and storage bins of drugs with problematic names, packages, and labels.	22%	39%	39%
Special alerts are built into the computer, as necessary, to remind practitioners about problematic or look-alike drug names, packaging, or labeling.	37%	25%	39%



	Degree of Implementation		
	None	Partial	Full
Computer mnemonics are designed to minimize selection of the wrong medication or strength.	47%	26%	28%

Specific items in self assessment - report of current activities: Standardization, Storage, & Distribution

	Degree of Implementation		entation
	None	Partial	Full
Access to targeted high-alert medications such as anti-coagulants and oral hypoglycemic drugs, and other problem products, has been safeguarded through constraints (such as drug placement in locked area, removal from "fast mover" areas where it might be "grabbed" incorrectly, etc.) to reduce potential for dispensing errors.	47%	30%	22%
An automated dispensing system that incorporates robotics and/or bar-code verification systems is used to support the dispensing system in the pharmacy.	44%	19%	37%
A mechanism exists to identify the reasons that a prescription has not been picked up after being prepared.	33%	26%	41%

Specific items in self assessment - report of current activities: Medication Device Acquisition, Use, and Monitoring

	Degree of Implementation		
	None	Partial	Full
Patients are instructed on the proper use and maintenance of devices dispensed from the pharmacy (e.g., glucose monitors, humidifiers, spacers used with inhalers, etc.).	8%	58%	34%



Specific items in self assessment - report of current activities: Environmental Factors

	Degree of Implementation		
	None	Partial	Full
Areas where drug orders are transcribed and/or entered into computer systems are isolated and relatively free of distractions, noises, and unnecessary chatter.	31%	42%	27%
The physical layout of the pharmacy is designed to minimize distractions for pharmacists during the final check in the prescription verification process.	29%	36%	35%
When dispensing prescriptions, staff work with one drug product at a time and affix the label to the patient's prescription container before working on the next prescription.	7%	35%	58%
A device is available and used to hold prescription information near the computer monitor, at eye level, in order to improve visibility when entering orders.	21%	16%	61%
Prescriptions are scanned into the computer or received electronically via a hand held device or computer.	86%	3%	10%
A magnifying box or lens is in a fixed location and used to facilitate readability of prescriptions and labels.	33%	10%	57%

Specific items in self assessment - report of current activities: Staff Competency and Education

	Degree of Implementation		
	None	Partial	Full
Pharmacy staff is sufficiently trained on the proper use and maintenance of devices dispensed from the pharmacy (e.g., glucose monitors, humidifiers, spacers used with inhalers, etc.)	21%	56%	22%



	Degree of Implementation		
	None	Partial	Full
 Pharmacists and technicians receive <u>ongoing</u> information about: Medication errors occurring within the organization Error-prone situations Errors occurring in other pharmacies Strategies to prevent such errors 	20%	45%	34%
Medication errors and ways to avoid them are routinely discussed at staff meetings and among pharmacists, technicians, and managers.	16%	43%	42%

Specific items in self assessment - report of current activities: Patient Education

	Degree of Implementation		
	None	Partial	Full
Adequate time is budgeted by management for patient counseling activities.	14%	54%	32%
A suitable private area with minimal distractions is available to provide patient counseling.	25%	41%	34%
Clerks fully disclose the intent of the proof of counseling log before asking patients or caregivers to sign the log.	45%	24%	30%
Criteria have been established to trigger required counseling and a system is in place to alert the pharmacist of this need.	21%	31%	47%
When counseling is provided, the patient's drug container is opened in front of the patient/caregiver to verify the appearance of the medication.	28%	56%	16%
Patients are informed about the potential for error with drugs that have been known to be problematic and are provided with strategies to help prevent such an occurrence.	35%	44%	21%



Specific items in self assessment - report of current activities: Quality Processes

	Degree of Implementation		
	None	Partial	Full
Pharmacists and technicians are provided with regular feedback about errors reported in the pharmacy, hazardous situations, and error reduction strategies that are being implemented.	20%	39%	41%
Management and staff routinely read and use published error experiences <u>from other</u> organizations to proactively target improvements in the medication dispensing process.	37%	38%	25%
Pharmacists recognize the value of reporting via external reporting programs such as the ISMP MERP.	40%	26%	34%
Pharmacy management supports practitioner reporting via external reporting programs such as the ISMP MERP.	43%	22%	35%